{"b30dee6bc325fb80ce9f852b4d1b0593f4cbe685": [["In view of the ongoing COVID-19 pandemic and for avoiding super-spreader events, Saudi Arabia on June 22, 2020 announced restriction of international visitors for the 2020 annual Hajj pilgrimage to Mecca and for the domestic population with chronic diseases and aged 65 years and older [1] .", [["chronic diseases", "DISEASE", 241, 257], ["the ongoing COVID", "TEST", 11, 28], ["chronic diseases", "PROBLEM", 241, 257], ["chronic", "OBSERVATION_MODIFIER", 241, 248], ["diseases", "OBSERVATION", 249, 257]]], ["Although the holy sites will remain open, limiting access to no more than 1,000 people (who already reside in Saudi Arabia) to the holy sites that would normally be crowded by 3 to 5 million pilgrims will enable the health authorities assure adequate physical distancing and implement disinfection measures.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["the holy sites", "PROBLEM", 9, 23], ["disinfection measures", "TREATMENT", 285, 306]]], ["The new restrictions add to the existing restrictions on the less well-known year-around pilgrimage called Umra that was suspended on March 3, 2020 [2, 3] .", [["new", "OBSERVATION_MODIFIER", 4, 7]]]], "PMC7404578": [["ETHICAL APPROVAL AND CONSENT TO PARTICIPATEThis study was approved by the Research Ethics Commission of Tongji Hospital of Huazhong University of Science and Technology (TJ\u2010IRB20200406) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.", [["the study", "TEST", 225, 234], ["the procedures", "TREATMENT", 243, 257], ["the routine care", "TREATMENT", 287, 303]]], ["The informed consents were waived by the Ethics Commission of Tongji Hospital of Huazhong University of Science and Technology.CONFLICT OF INTERESTThe authors have no conflicts of interest to declare.AUTHOR CONTRIBUTORSQG had full access to all data in the study and take responsibility for the integrity of data and the accuracy of the data analysis.", [["the study", "TEST", 253, 262], ["the data analysis", "TEST", 333, 350]]], ["SZ, SW, YG, SX, RY, YW, and YY collected the clinical data.", [["SZ", "PROBLEM", 0, 2]]], ["XJ, JC, YaY, CS, NJ, PC, JL, XZ, WG, XL, and GC double\u2010checked and entered the data into database.", [["GC double\u2010checked", "TEST", 45, 62], ["JC", "OBSERVATION", 4, 6], ["JL", "ANATOMY", 25, 27]]], ["DL, RL, XF, CL, and QG analyzed the clinical records.", [["DL", "TEST", 0, 2], ["CL", "TEST", 12, 14], ["RL", "ANATOMY_MODIFIER", 4, 6], ["XF", "ANATOMY", 8, 10]]], ["RL, RY, YW, XF, YY, HL, and AD drafted the manuscript.", [["AD", "DISEASE", 28, 30]]], ["DL, QG, RL, RY, YW, XF, and YY analyzed and interpreted the data.", [["RL", "ANATOMY_MODIFIER", 8, 10]]], ["CL, JS, and SK advised on the conception and design of the study.", [["SK", "CHEMICAL", 12, 14], ["CL", "MULTI-TISSUE_STRUCTURE", 0, 2], ["the study", "TEST", 55, 64], ["JS", "ANATOMY", 4, 6]]], ["DL, CL, QG, and AD conceptualized and designed the study, supervised the project, and revised the manuscript.", [["DL", "TEST", 0, 2], ["CL", "TEST", 4, 6], ["the study", "TEST", 47, 56], ["CL", "OBSERVATION", 4, 6]]], ["All authors vouch for the respective data and analysis, revised, approved the final version, and agreed to publish the manuscript.", [["the respective data", "TEST", 22, 41]]], ["DL, RL, RY, YW, XF, and YY share first authorship, the order in which they are listed was determined by workload.", [["RL", "ANATOMY_MODIFIER", 4, 6]]]], "PMC6142664": [["Emerging and re-emerging viral infections have been a major threat to public health worldwide, since their recognition in the late 20th century [1].", [["viral infections", "DISEASE", 25, 41], ["re-emerging viral infections", "PROBLEM", 13, 41]]], ["These infectious diseases include those caused by newly identified viruses, previously known viruses that acquired additional virulence traits, and those showing spread to unaffected regions.", [["infectious diseases", "DISEASE", 6, 25], ["These infectious diseases", "PROBLEM", 0, 25], ["newly identified viruses", "PROBLEM", 50, 74], ["previously known viruses", "PROBLEM", 76, 100], ["acquired additional virulence traits", "PROBLEM", 106, 142], ["infectious", "OBSERVATION", 6, 16], ["viruses", "OBSERVATION", 67, 74], ["viruses", "OBSERVATION", 93, 100]]], ["In the last ten years, re-emergence has been noted for Zika, Ebola, MERS, Dengue, Chikungunya and avian influenza, while SFTS (severe fever with thrombocytopenia syndrome) was recognized to be caused by a novel virus.", [["Ebola", "DISEASE", 61, 66], ["Dengue", "DISEASE", 74, 80], ["Chikungunya", "DISEASE", 82, 93], ["avian influenza", "DISEASE", 98, 113], ["SFTS", "DISEASE", 121, 125], ["fever", "DISEASE", 134, 139], ["thrombocytopenia syndrome", "DISEASE", 145, 170], ["Ebola", "ORGANISM", 61, 66], ["Chikungunya", "ORGANISM", 82, 93], ["avian influenza", "ORGANISM", 98, 113], ["Chikungunya", "SPECIES", 82, 93], ["avian influenza", "SPECIES", 98, 113], ["Zika", "PROBLEM", 55, 59], ["Ebola", "PROBLEM", 61, 66], ["MERS", "PROBLEM", 68, 72], ["Dengue", "PROBLEM", 74, 80], ["Chikungunya", "PROBLEM", 82, 93], ["avian influenza", "PROBLEM", 98, 113], ["SFTS (severe fever", "PROBLEM", 121, 139], ["thrombocytopenia syndrome", "PROBLEM", 145, 170], ["a novel virus", "PROBLEM", 203, 216]]], ["These diseases are free to move across national borders according to rapid human mobility via global airline network.", [["human", "ORGANISM", 75, 80], ["airline network", "MULTI-TISSUE_STRUCTURE", 101, 116], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["These diseases", "PROBLEM", 0, 14], ["diseases", "OBSERVATION", 6, 14], ["free", "OBSERVATION_MODIFIER", 19, 23]]], ["With this background, any novel infectious disease anywhere in the world may have the potential for global spread.", [["any novel infectious disease", "PROBLEM", 22, 50], ["global spread", "PROBLEM", 100, 113], ["infectious", "OBSERVATION", 32, 42], ["may have the potential for", "UNCERTAINTY", 73, 99], ["global", "OBSERVATION_MODIFIER", 100, 106], ["spread", "OBSERVATION", 107, 113]]]], "PMC6777354": [["IntroductionHuman norovirus (HuNoV) is a major causative pathogen of acute viral gastroenteritis (de Graaf et al., 2016).", [["norovirus", "DISEASE", 18, 27], ["HuNoV", "CHEMICAL", 29, 34], ["viral gastroenteritis", "DISEASE", 75, 96], ["IntroductionHuman norovirus", "ORGANISM", 0, 27], ["HuNoV", "ORGANISM", 29, 34], ["HuNoV", "SPECIES", 29, 34], ["IntroductionHuman norovirus (HuNoV", "PROBLEM", 0, 34], ["acute viral gastroenteritis", "PROBLEM", 69, 96], ["norovirus", "OBSERVATION", 18, 27], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["viral gastroenteritis", "OBSERVATION", 75, 96]]], ["Although HuNoV is most prevalent during autumn and winter in the northern hemisphere, the virus can be detected throughout the year (Ahmed et al., 2013).", [["HuNoV", "GENE_OR_GENE_PRODUCT", 9, 14], ["HuNoV", "PROTEIN", 9, 14], ["HuNoV", "PROBLEM", 9, 14], ["the virus", "PROBLEM", 86, 95], ["HuNoV", "OBSERVATION", 9, 14], ["most prevalent", "OBSERVATION_MODIFIER", 18, 32], ["autumn", "OBSERVATION", 40, 46], ["northern hemisphere", "ANATOMY", 65, 84], ["virus", "OBSERVATION", 90, 95]]], ["A previous report suggested that approximately 680 million people annually suffer from gastroenteritis due to HuNoV infection worldwide (Kirk et al., 2015).", [["gastroenteritis", "DISEASE", 87, 102], ["infection", "DISEASE", 116, 125], ["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["HuNoV", "SPECIES", 110, 115], ["gastroenteritis", "PROBLEM", 87, 102], ["HuNoV infection", "PROBLEM", 110, 125], ["gastroenteritis", "OBSERVATION", 87, 102], ["HuNoV", "OBSERVATION_MODIFIER", 110, 115], ["infection", "OBSERVATION", 116, 125]]], ["Molecular epidemiological studies have indicated that distinct GII.4 variants have recurrently emerged every 2\u20133 years in the past decade to cause pandemics of gastroenteritis in all aged individuals (Bull et al., 2010).", [["gastroenteritis", "DISEASE", 160, 175], ["Molecular epidemiological studies", "TEST", 0, 33], ["distinct GII", "PROBLEM", 54, 66], ["gastroenteritis", "PROBLEM", 160, 175], ["distinct", "OBSERVATION_MODIFIER", 54, 62], ["GII", "OBSERVATION", 63, 66], ["gastroenteritis", "OBSERVATION", 160, 175]]], ["Furthermore, GII.P17-GII.17 (Kawasaki2014 variant) has suddenly been prevalent since 2014 in various countries including Japan, China, South Korea, Italy, Romania, Argentina, Brazil, and the USA (Chan et al., 2015; Fu et al., 2015; Matsushima et al., 2015; Medici et al., 2015; Dang Thanh et al., 2016; Dinu et al., 2016; Cannon et al., 2017; Degiuseppe et al., 2017; Silva et al., 2017).", [["P17", "GENE_OR_GENE_PRODUCT", 17, 20], ["GII.17", "GENE_OR_GENE_PRODUCT", 21, 27], ["Kawasaki2014", "GENE_OR_GENE_PRODUCT", 29, 41], ["P17", "TEST", 17, 20]]], ["However, the epidemiology of this virus over a long period of time is unclear at present.IntroductionHuNoV belongs to the genus Norovirus of the family Caliciviridae, and it is further genetically classified into three genogroups, GI, GII, and GIV.", [["Caliciviridae", "GENE_OR_GENE_PRODUCT", 152, 165], ["this virus", "PROBLEM", 29, 39], ["the family Caliciviridae", "TREATMENT", 141, 165], ["Norovirus", "OBSERVATION", 128, 137]]], ["Genetic analyses have shown that HuNoV GI and GII can be further classified into 9 and 22 genotypes, respectively (Kroneman et al., 2013).", [["HuNoV GI", "ORGANISM", 33, 41], ["Genetic analyses", "TEST", 0, 16]]], ["Of these, many genotypes have been associated with gastroenteritis outbreaks throughout the world (Hoa Tran et al., 2013).", [["gastroenteritis", "DISEASE", 51, 66], ["gastroenteritis", "PROBLEM", 51, 66], ["associated with", "UNCERTAINTY", 35, 50], ["gastroenteritis", "OBSERVATION", 51, 66]]], ["The genomes of noroviruses contain three open reading frames and encodes six non-structural proteins, including the RNA-dependent RNA polymerase and the two capsid proteins VP1 and VP2 (de Graaf et al., 2016).IntroductionMolecular evolutionary analysis based on advanced bioinformatics technologies is a powerful tool to better understand not only the phylogeny of pathogens, but also their antigenicity (Bok et al., 2009; Siebenga et al., 2010; Boon et al., 2011; Lu et al., 2016; Parra et al., 2017; Tohma et al., 2017; Nagasawa et al., 2018).", [["noroviruses", "ORGANISM", 15, 26], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 116, 144], ["VP1", "GENE_OR_GENE_PRODUCT", 173, 176], ["VP2", "GENE_OR_GENE_PRODUCT", 181, 184], ["open reading frames", "DNA", 41, 60], ["non-structural proteins", "PROTEIN", 77, 100], ["RNA-dependent RNA polymerase", "PROTEIN", 116, 144], ["capsid proteins", "PROTEIN", 157, 172], ["VP1", "PROTEIN", 173, 176], ["VP2", "PROTEIN", 181, 184], ["noroviruses", "PROBLEM", 15, 26], ["encodes six non-structural proteins", "PROBLEM", 65, 100], ["the RNA", "TEST", 112, 119], ["dependent RNA polymerase", "PROBLEM", 120, 144], ["pathogens", "PROBLEM", 365, 374], ["noroviruses", "OBSERVATION", 15, 26], ["non-structural proteins", "OBSERVATION", 77, 100]]], ["Furthermore, next-generation sequencing technologies are also useful for the comprehensive analysis of various virus genomes (Qui\u00f1ones-Mateu et al., 2014).", [["the comprehensive analysis", "TEST", 73, 99], ["various virus genomes", "PROBLEM", 103, 124]]], ["In this study, we used both these methodologies to conduct a detailed molecular evolutionary analysis of the VP1 and RdRp regions of GII.P17-GII.17 strains detected in various countries.Sample Preparation and Ethics Statement ::: Materials and MethodsA total of 76 strains of GII.P17-GII.17 detected in Miyagi (16 strains), Kanagawa (11 samples), Saitama (10 samples), Ibaraki (9 strains), Gunma (7 strains), Aichi (7 strains), Hiroshima (5 strains), Tochigi (4 strains), Fukuoka (3 strains), Yamaguchi (3 strains), and Aomori (1 strain) prefectures from 2013 to 2017 were sequenced in this study.", [["samples", "ANATOMY", 337, 344], ["samples", "ANATOMY", 359, 366], ["VP1", "GENE_OR_GENE_PRODUCT", 109, 112], ["P17-GII", "GENE_OR_GENE_PRODUCT", 137, 144], ["P17-GII", "GENE_OR_GENE_PRODUCT", 280, 287], ["samples", "CANCER", 337, 344], ["Gunma", "ORGANISM", 390, 395], ["Aichi", "ORGANISM", 409, 414], ["VP1 and RdRp regions", "DNA", 109, 129], ["P17", "PROTEIN", 137, 140], ["P17", "PROTEIN", 280, 283], ["this study", "TEST", 3, 13], ["the VP1 and RdRp regions of GII", "PROBLEM", 105, 136], ["17 strains", "PROBLEM", 145, 155], ["GII", "PROBLEM", 276, 279], ["Saitama", "TEST", 347, 354], ["Ibaraki (9 strains)", "PROBLEM", 369, 388], ["Gunma (7 strains)", "PROBLEM", 390, 407], ["Aichi (7 strains)", "PROBLEM", 409, 426], ["Hiroshima (5 strains)", "PROBLEM", 428, 449], ["Tochigi (4 strains", "PROBLEM", 451, 469], ["Fukuoka (3 strains)", "PROBLEM", 472, 491], ["Yamaguchi (3 strains", "TREATMENT", 493, 513], ["Aomori (1 strain)", "TREATMENT", 520, 537], ["this study", "TEST", 586, 596], ["GII", "ANATOMY", 133, 136]]], ["Fecal samples were collected from patients with acute gastroenteritis associated with HuNoV infection under compliance with the Food Sanitation Law and the Law Concerning the Prevention of Infections and Medical Care for Patients of Infections of Japan.", [["Fecal samples", "ANATOMY", 0, 13], ["gastroenteritis", "DISEASE", 54, 69], ["HuNoV infection", "DISEASE", 86, 101], ["Infections", "DISEASE", 189, 199], ["Infections", "DISEASE", 233, 243], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["patients", "ORGANISM", 34, 42], ["Patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 34, 42], ["Patients", "SPECIES", 221, 229], ["HuNoV", "SPECIES", 86, 91], ["Fecal samples", "TEST", 0, 13], ["acute gastroenteritis", "PROBLEM", 48, 69], ["HuNoV infection", "PROBLEM", 86, 101], ["Medical Care", "TREATMENT", 204, 216], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["gastroenteritis", "OBSERVATION", 54, 69], ["HuNoV infection", "OBSERVATION", 86, 101], ["Infections", "OBSERVATION", 189, 199]]], ["Informed consent was obtained from all participants, which was acquired from the subjects or their legally acceptable representatives for sample donation.", [["participants", "SPECIES", 39, 51], ["sample donation", "TREATMENT", 138, 153]]], ["The personal data of the patients was anonymized.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["To perform extraneous study (this study) and due to the lack of written informed consent, this study obtained ethical approval from the Research and Ethical Committees for the Use of Human Subjects of the National Institute of Infectious Diseases, Tokyo, Japan (No. 576).", [["Infectious Diseases", "DISEASE", 227, 246], ["Human", "ORGANISM", 183, 188], ["Human", "SPECIES", 183, 188], ["extraneous study", "TEST", 11, 27], ["this study", "TEST", 29, 39], ["this study", "TEST", 90, 100], ["Infectious", "OBSERVATION", 227, 237]]], ["All methods were conducted in accordance with the approved guidelines.", [["All methods", "TREATMENT", 0, 11]]], ["Information on the samples is given in Table S1.", [["samples", "ANATOMY", 19, 26], ["the samples", "TEST", 15, 26]]], ["RNA was extracted from 10% suspensions of fecal samples in phosphate buffered saline using a QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany).", [["fecal samples", "ANATOMY", 42, 55], ["phosphate", "CHEMICAL", 59, 68], ["phosphate", "CHEMICAL", 59, 68], ["fecal samples", "ORGANISM_SUBSTANCE", 42, 55], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 59, 84], ["RNA", "RNA", 0, 3], ["fecal samples", "TEST", 42, 55], ["phosphate buffered saline", "TREATMENT", 59, 84], ["a QIAamp", "TREATMENT", 91, 99], ["fecal", "ANATOMY", 42, 47]]], ["The extracted RNA was subjected to sequencing as described below.Sequencing ::: Materials and MethodsSequencing was performed with Sanger and next-generation sequencers.", [["The extracted RNA", "PROBLEM", 0, 17], ["MethodsSequencing", "TREATMENT", 94, 111]]], ["For Sanger sequencing, a reverse transcription\u2013polymerase chain reaction (RT-PCR) was first performed for 30 min at 45\u00b0C and then 2 min at 94\u00b0C, followed by a total of 45 cycles of 30 s at 98\u00b0C, 30 s at 55\u00b0C and 90 s at 68\u00b0C, and then a final extension of 7 min at 68\u00b0C using specific primers for the VP1 and RdRp regions and a PrimeScript II High Fidelity One Step RT-PCR kit (TaKaRa, Shiga, Japan; Table S2).", [["C", "GENE_OR_GENE_PRODUCT", 268, 269], ["VP1", "GENE_OR_GENE_PRODUCT", 301, 304], ["VP1 and RdRp regions", "DNA", 301, 321], ["Sanger sequencing", "TEST", 4, 21], ["a reverse transcription\u2013polymerase chain reaction", "PROBLEM", 23, 72], ["RT-PCR", "TEST", 74, 80], ["specific primers", "TREATMENT", 276, 292], ["the VP1 and RdRp regions", "TREATMENT", 297, 321], ["a PrimeScript II", "TREATMENT", 326, 342], ["PCR kit", "TEST", 369, 376]]], ["Cycle sequencing was performed for 1 min at 96\u00b0C, followed by a total of 30 cycles of 10 s at 96\u00b0C, 10 s at 50\u00b0C and 2 min at 60\u00b0C using a BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Carlsbad, California, USA).", [["C", "GENE_OR_GENE_PRODUCT", 129, 130], ["Cycle sequencing", "TEST", 0, 16], ["a BigDye Terminator", "TREATMENT", 137, 156]]], ["The DNA sequences were analyzed using a 3500 Genetic Analyser (Applied Biosystems).", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA sequences", "DNA", 4, 17], ["The DNA sequences", "TEST", 0, 17]]], ["Full-length nucleotide sequences of the VP1 and RdRp regions were acquired using the primer walking method.", [["nucleotide", "CHEMICAL", 12, 22], ["VP1", "GENE_OR_GENE_PRODUCT", 40, 43], ["VP1 and RdRp regions", "DNA", 40, 60], ["the primer walking method", "TEST", 81, 106], ["VP1", "ANATOMY", 40, 43]]], ["Data analysis was performed using CLC Genomics Workbench v8.0.1 (Qiagen).", [["Data analysis", "TEST", 0, 13]]], ["HuNoV genotypes were determined using the Norovirus Genotyping Tool (version 2.0) and the Human Calicivirus Typing Tool1 (Kroneman et al., 2011).Construction of Datasets for Bioinformatics ::: Materials and MethodsAll full-length nucleotide sequences of the VP1 and RdRp regions of GII.17, including information on sample collection years and no mixed nucleotides, were obtained from GenBank2 (accessed on 29 August, 2017).", [["nucleotide", "CHEMICAL", 230, 240], ["nucleotides", "CHEMICAL", 352, 363], ["HuNoV", "ORGANISM", 0, 5], ["Human", "ORGANISM", 90, 95], ["VP1", "GENE_OR_GENE_PRODUCT", 258, 261], ["full-length nucleotide sequences", "DNA", 218, 250], ["VP1 and RdRp regions", "DNA", 258, 278], ["Human", "SPECIES", 90, 95], ["HuNoV", "SPECIES", 0, 5], ["Human Calicivirus Typing Tool1", "SPECIES", 90, 120], ["HuNoV genotypes", "PROBLEM", 0, 15], ["Methods", "TREATMENT", 207, 214], ["nucleotide sequences", "TEST", 230, 250], ["mixed nucleotides", "PROBLEM", 346, 363], ["VP1", "ANATOMY", 258, 261], ["GII", "ANATOMY", 282, 285]]], ["For the GII.P17-GII.17 genotype, only sequences with information on sample collection years and months were used in this study.", [["sample", "ANATOMY", 68, 74], ["P17-GII", "GENE_OR_GENE_PRODUCT", 12, 19], ["P17", "PROTEIN", 12, 15], ["this study", "TEST", 116, 126]]], ["Moreover, nine sequences associated with some recent outbreaks of GII.P17-GII.17 (Sakon et al., 2018) were combined with those of the new Japanese strains above.", [["GII", "DISEASE", 66, 69], ["P17", "GENE_OR_GENE_PRODUCT", 70, 73], ["nine sequences", "TEST", 10, 24], ["GII", "PROBLEM", 66, 69], ["P17", "TEST", 70, 73], ["outbreaks", "OBSERVATION", 53, 62]]], ["To construct time-scaled phylogenetic tree, we added representative VP1 sequences of all GII genotypes, including porcine NoV GII (GII.11, GII.18, and GII.19) and other HuNoV GII genotypes (18 strains), as well as an outgroup strain of HuNoV GI genotype (GI.1) to the dataset of the VP1 region (resulting in a total of 365 strains).", [["porcine", "ORGANISM", 114, 121], ["NoV GII", "ORGANISM", 122, 129], ["HuNoV GII", "ORGANISM", 169, 178], ["HuNoV GI", "ORGANISM", 236, 244], ["VP1", "ORGANISM", 283, 286], ["VP1 sequences", "DNA", 68, 81], ["VP1 region", "DNA", 283, 293], ["porcine", "SPECIES", 114, 121], ["porcine NoV GII", "SPECIES", 114, 129], ["representative VP1 sequences", "TEST", 53, 81], ["GII", "TEST", 131, 134], ["GII", "TEST", 139, 142], ["other HuNoV GII genotypes (18 strains)", "PROBLEM", 163, 201], ["VP1 region", "ANATOMY", 283, 293]]], ["The representative RdRp sequences of the GII genotypes, including porcine NoV (GII.P11 and GII.P18) and other HuNoV GII genotypes (20 strains), as well as an outgroup strain of HuNoV GI genotype (GI.P1), were appended to produce an RdRp dataset consisting of 156 strains (Table S1).", [["porcine NoV", "ORGANISM", 66, 77], ["P11", "GENE_OR_GENE_PRODUCT", 83, 86], ["GII", "GENE_OR_GENE_PRODUCT", 91, 94], ["P18", "GENE_OR_GENE_PRODUCT", 95, 98], ["HuNoV GII", "GENE_OR_GENE_PRODUCT", 110, 119], ["HuNoV GI", "ORGANISM", 177, 185], ["RdRp sequences", "DNA", 19, 33], ["porcine", "SPECIES", 66, 73], ["porcine NoV", "SPECIES", 66, 77], ["the GII genotypes", "TREATMENT", 37, 54], ["other HuNoV GII genotypes", "PROBLEM", 104, 129], ["an RdRp dataset", "PROBLEM", 229, 244], ["RdRp", "OBSERVATION", 232, 236]]], ["The constructed datasets were aligned with MAFFT software (Katoh and Standley, 2013).Time-Scaled Phylogenetic Trees ::: Materials and MethodsPhylogenetic trees with molecular clocks were generated by the Bayesian Markov Chain Monte Carlo (MCMC) method using the BEAST2 package v2.4.8 (Bouckaert et al., 2014).", [["the BEAST2 package", "TREATMENT", 258, 276]]], ["Best substitution models (GTR+\u0393+I for both VP1 and RdRp) were determined for the constructed datasets (365 strains for VP1 and 156 strains for the RdRp) by comparison of the Bayesian Information Criterion (BIC) values using jModelTest2 software (Guindon and Gascuel, 2003; Darriba et al., 2012).", [["VP1", "GENE_OR_GENE_PRODUCT", 43, 46], ["VP1", "PROTEIN", 43, 46], ["RdRp", "PROTEIN", 51, 55], ["VP1", "PROTEIN", 119, 122], ["RdRp", "PROTEIN", 147, 151], ["Best substitution models", "TEST", 0, 24], ["GTR", "TEST", 26, 29], ["both VP1 and RdRp", "TEST", 38, 55], ["the constructed datasets", "PROBLEM", 77, 101], ["VP1", "TEST", 119, 122], ["the RdRp", "TREATMENT", 143, 151]]], ["Appropriate clock and tree prior models (relaxed clock exponential and coalescent exponential population tree prior for both VP1 and RdRp) were selected by path-sampling/stepping stone-sampling marginal-likelihood estimation using the BEAST2 package (Baele et al., 2012).", [["VP1", "DNA", 125, 128], ["RdRp", "PROTEIN", 133, 137], ["tree prior models", "TREATMENT", 22, 39], ["VP1 and RdRp", "TREATMENT", 125, 137], ["sampling/stepping stone", "PROBLEM", 161, 184], ["tree", "OBSERVATION_MODIFIER", 22, 26], ["stone", "OBSERVATION", 179, 184]]], ["The MCMC runs were conducted with chain lengths of 930,000,000 steps with sampling every 16,000 steps for VP1, and with chain lengths of 465,000,000 steps with sampling every 8,000 steps for RdRp.", [["VP1", "PROTEIN", 106, 109], ["RdRp", "PROTEIN", 191, 195], ["The MCMC runs", "TEST", 0, 13], ["VP1", "TEST", 106, 109], ["RdRp", "PROBLEM", 191, 195]]], ["The analyzed data was evaluated by the effective sample sizes (ESS) values using Tracer3 software, and values of 200 or more were accepted.", [["The analyzed data", "TEST", 0, 17], ["Tracer3 software", "TEST", 81, 97], ["values", "TEST", 103, 109]]], ["Maximum clade credibility trees were generated by discarding the first 10% of trees (burn-in) using TreeAnnotator v2.4.8 in the BEAST2 package.", [["TreeAnnotator", "TREATMENT", 100, 113], ["the BEAST2 package", "TREATMENT", 124, 142]]], ["Branch reliability was supported by highest posterior densities (HPDs) of 95%.", [["highest posterior densities", "PROBLEM", 36, 63], ["highest", "OBSERVATION_MODIFIER", 36, 43], ["posterior", "OBSERVATION_MODIFIER", 44, 53], ["densities", "OBSERVATION", 54, 63]]], ["Moreover, the evolutionary rates of GII.P17-GII.17 strains were estimated as described above.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 40, 47], ["P17", "PROTEIN", 40, 43], ["GII", "PROBLEM", 36, 39], ["17 strains", "PROBLEM", 48, 58]]], ["The analyzed parameters with substitution, clock, and tree prior models are shown in Table 1.", [["substitution, clock", "TREATMENT", 29, 48], ["tree prior models", "TREATMENT", 54, 71]]], ["In this study, the evolutionary rates of overall clusters in the GII.P17-GII.17 strains were calculated since the rate of a cluster could not be estimated due to the limited number of strains available for analysis.Bayesian Skyline Plot ::: Materials and MethodsTransition of effective population sizes was estimated by a Bayesian skyline plot using the BEAST2 package v2.4.8.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 69, 76], ["P17", "PROTEIN", 69, 72], ["this study", "TEST", 3, 13], ["17 strains", "PROBLEM", 77, 87], ["strains", "PROBLEM", 184, 191], ["analysis", "TEST", 206, 214], ["Materials", "TREATMENT", 241, 250], ["effective population sizes", "PROBLEM", 276, 302], ["the BEAST2 package", "TREATMENT", 350, 368], ["clusters", "OBSERVATION_MODIFIER", 49, 57], ["GII", "ANATOMY", 65, 68], ["effective", "OBSERVATION_MODIFIER", 276, 285], ["population", "OBSERVATION_MODIFIER", 286, 296], ["sizes", "OBSERVATION_MODIFIER", 297, 302]]], ["Appropriate substitution models were selected based on comparison of the BIC values in the dataset, including 337 strains of the Kawasaki2014 variant in the VP1 region.", [["Kawasaki2014", "GENE_OR_GENE_PRODUCT", 129, 141], ["VP1 region", "DNA", 157, 167], ["Appropriate substitution models", "TREATMENT", 0, 31], ["the BIC values", "TEST", 69, 83], ["VP1", "ANATOMY", 157, 160], ["region", "ANATOMY_MODIFIER", 161, 167]]], ["The clock models were appropriately selected on the basis of path-sampling/stepping stone-sampling marginal-likelihood estimation.", [["The clock models", "TREATMENT", 0, 16], ["path", "TEST", 61, 65], ["stepping stone", "PROBLEM", 75, 89], ["stone", "OBSERVATION", 84, 89]]], ["After evaluation based on the ESS values, the Bayesian skyline plot was generated by Tracer3 software.Phylogenetic Distances ::: Materials and MethodsPhylogenetic trees were created using the maximum likelihood method in MEGA7 software (Kumar et al., 2016).", [["evaluation", "TEST", 6, 16], ["the ESS values", "TEST", 26, 40], ["the Bayesian skyline plot", "TEST", 42, 67]]], ["Best substitution models (GTR+\u0393+I for VP1 and K80+\u0393 for RdRp) were selected using the jModelTest2.", [["K80+\u0393", "GENE_OR_GENE_PRODUCT", 46, 51], ["VP1", "PROTEIN", 38, 41], ["K80", "PROTEIN", 46, 49], ["\u0393", "PROTEIN", 50, 51], ["RdRp", "PROTEIN", 56, 60], ["jModelTest2", "PROTEIN", 86, 97], ["Best substitution models", "TEST", 0, 24], ["GTR", "TEST", 26, 29], ["VP1", "TEST", 38, 41], ["K80", "TEST", 46, 49], ["RdRp", "PROBLEM", 56, 60]]], ["Branch reliability was supported by 1,000 replications of bootstrap values.", [["bootstrap values", "TEST", 58, 74]]], ["Phylogenetic distances between GII.17 strains were calculated by Patristic software (Fourment and Gibbs, 2006).Construction of Three-Dimensional Structures, Conformational Epitope Analyses, and Selective Pressure Analyses ::: Materials and MethodsStructural models of the VP1 and RdRp proteins of HuNoV [Hu/GII/JP/1976/GII.17/Tokyo/27-3: AB684681 (VP1), Hu/GII/NE/1995/GII.P3/Amsterdam/1: KJ194500 (RdRp), Hu/GII/JP/2014/GII.P17-GII.17/Kawasaki323: AB983218 (VP1 and RdRp), Hu/GII/JP/2015/GII.P17-GII.17/Kawasaki308: LC037415 (VP1 and RdRp)] were generated based on homology modeling using the MODELLER software v9.15 (Webb and Sali, 2014).", [["VP1", "GENE_OR_GENE_PRODUCT", 272, 275], ["HuNoV", "GENE_OR_GENE_PRODUCT", 297, 302], ["VP1", "ORGANISM", 348, 351], ["RdRp", "ORGANISM", 399, 403], ["P17-GII", "GENE_OR_GENE_PRODUCT", 425, 432], ["VP1", "GENE_OR_GENE_PRODUCT", 459, 462], ["P17-GII", "GENE_OR_GENE_PRODUCT", 493, 500], ["Kawasaki308", "GENE_OR_GENE_PRODUCT", 504, 515], ["LC037415", "GENE_OR_GENE_PRODUCT", 517, 525], ["VP1", "GENE_OR_GENE_PRODUCT", 527, 530], ["RdRp", "GENE_OR_GENE_PRODUCT", 535, 539], ["VP1", "PROTEIN", 272, 275], ["RdRp proteins", "PROTEIN", 280, 293], ["HuNoV", "PROTEIN", 297, 302], ["GII", "PROTEIN", 319, 322], ["NE", "PROTEIN", 361, 363], ["GII", "PROTEIN", 369, 372], ["2014", "PROTEIN", 416, 420], ["P17", "PROTEIN", 425, 428], ["VP1", "PROTEIN", 459, 462], ["RdRp", "PROTEIN", 467, 471], ["2015", "PROTEIN", 484, 488], ["GII", "PROTEIN", 489, 492], ["P17", "PROTEIN", 493, 496], ["VP1", "PROTEIN", 527, 530], ["RdRp", "PROTEIN", 535, 539], ["Hu/GII/JP/1976/GII", "SPECIES", 304, 322], ["17/Tokyo/27-3: AB684681 (VP1), Hu/GII/NE/1995/GII", "SPECIES", 323, 372], ["Hu/GII/JP/2015/GII", "SPECIES", 474, 492], ["Phylogenetic distances between GII", "PROBLEM", 0, 34], ["Conformational Epitope Analyses", "TEST", 157, 188], ["Selective Pressure Analyses", "TEST", 194, 221], ["MethodsStructural models", "TREATMENT", 240, 264], ["the VP1", "TEST", 268, 275], ["VP1", "TEST", 348, 351], ["Hu", "TEST", 354, 356], ["GII", "PROBLEM", 369, 372], ["VP1", "TEST", 459, 462], ["RdRp", "TEST", 467, 471], ["Hu", "TEST", 474, 476], ["VP1", "TEST", 527, 530], ["RdRp", "TEST", 535, 539], ["the MODELLER software v", "TEST", 590, 613], ["JP", "ANATOMY", 311, 313], ["JP", "ANATOMY", 413, 415], ["JP", "ANATOMY", 481, 483]]], ["Three crystal structures for VP1 (PDBID: 1IHM, 5F4M and 5LKC) and one for RdRp (PDBID: 1SH0) were used as the templates based on Basic Local Alignment Search Tool5 (BLAST) analyses of the proteins.", [["VP1", "PROTEIN", 29, 32], ["PDBID", "PROTEIN", 34, 39], ["1IHM", "PROTEIN", 41, 45], ["5F4M", "PROTEIN", 47, 51], ["5LKC", "PROTEIN", 56, 60], ["RdRp", "PROTEIN", 74, 78], ["PDBID", "PROTEIN", 80, 85], ["SH0", "PROTEIN", 88, 91], ["VP1", "TEST", 29, 32], ["PDBID", "TEST", 34, 39], ["1IHM", "TEST", 41, 45], ["5F4M", "TEST", 47, 51], ["RdRp", "PROBLEM", 74, 78]]], ["Amino acid sequences of the templates and the target strains were aligned using MAFFTash software (Standley et al., 2007; Katoh et al., 2009).", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["Amino acid sequences", "TEST", 0, 20], ["the target strains", "PROBLEM", 42, 60]]], ["The constructed structures were minimized using the GROMOS96, implemented by Swiss PDB Viewer v4.1 and evaluated by Ramachandran plots via the RAMPAGE server, which showed the favored regions of 96.1% \u00b1 0.26 (VP1) and 98.0% \u00b1 0.46 (RdRp), the allowed regions of 3.43% \u00b1 0.32 (VP1) and 1.47% \u00b1 0.32 (RdRp), and the outlier regions of 0.47% \u00b1 0.058 (VP1) and 0.57% \u00b1 0.15 (RdRp) (mean \u00b1 SD) of all residues in each structure (Guex and Peitsch, 1997; Lovell et al., 2003).", [["GROMOS96", "DNA", 52, 60], ["RdRp", "PROTEIN", 232, 236], ["VP1", "PROTEIN", 276, 279], ["RdRp", "PROTEIN", 299, 303], ["VP1", "PROTEIN", 348, 351], ["RdRp", "PROTEIN", 371, 375], ["the RAMPAGE server", "TEST", 139, 157], ["VP1", "TEST", 209, 212], ["RdRp", "TEST", 232, 236], ["VP1", "TEST", 276, 279], ["RdRp", "TEST", 299, 303], ["VP1", "TEST", 348, 351], ["RdRp", "TEST", 371, 375], ["outlier", "OBSERVATION_MODIFIER", 314, 321], ["all residues", "OBSERVATION", 392, 404]]], ["Conformational epitopes on the VP1 dimer structures of the GII.17 strains were predicted using DiscoTope 2.0, EPCES, and EPSVR programmes (Liang et al., 2007, 2010; Kringelum et al., 2012).", [["VP1 dimer structures", "PROTEIN", 31, 51], ["Conformational epitopes", "PROBLEM", 0, 23], ["DiscoTope", "TEST", 95, 104], ["GII", "ANATOMY", 59, 62]]], ["Cut-off values were set at \u22123.1 for the DiscoTope 2.0 and 81 for the EPCES and EPSVR in order to encompass epitopes on the VP1 of GII.17 identified by a previous in vitro study (Lindesmith et al., 2017).", [["EPSVR", "PROTEIN", 79, 84], ["epitopes", "PROTEIN", 107, 115], ["VP1", "PROTEIN", 123, 126], ["Cut", "TEST", 0, 3], ["the DiscoTope", "TEST", 36, 49], ["the EPCES", "TEST", 65, 74], ["EPSVR", "TREATMENT", 79, 84], ["the VP1 of GII", "TREATMENT", 119, 133], ["vitro study", "TEST", 165, 176]]], ["Consensus sites identified by more than one of the three tools and regions with two or more closely apposed residues of the sites on the VP1 dimer structures were determined to be conformational epitopes.", [["VP1 dimer", "PROTEIN", 137, 146], ["conformational epitopes", "PROTEIN", 180, 203], ["Consensus sites", "PROBLEM", 0, 15], ["conformational epitopes", "PROBLEM", 180, 203]]], ["Positive selection sites in the VP1 region of the GII.17 strains were predicted using the Fast, Unconstrained Bayesian AppRoximation (FUBAR) and Mixed Effects Model of Evolution (MEME) algorithms on the Datamonkey server (Pond and Frost, 2005; Delport et al., 2010; Murrell et al., 2012, 2013; Weaver et al., 2018).", [["VP1 region", "DNA", 32, 42], ["Positive selection sites", "PROBLEM", 0, 24], ["Unconstrained Bayesian AppRoximation (FUBAR)", "TREATMENT", 96, 140], ["selection sites", "OBSERVATION", 9, 24], ["VP1 region", "ANATOMY_MODIFIER", 32, 42], ["GII", "ANATOMY", 50, 53]]], ["Generally, FUBAR hypothesizes constant selection pressure at each site for the entire phylogeny and utilizes a Bayesian approach to estimate non-synonymous (dN) and synonymous (dS) substitution rates at each site.", [["FUBAR", "PROTEIN", 11, 16], ["a Bayesian approach", "TREATMENT", 109, 128], ["non-synonymous (dN)", "TREATMENT", 141, 160], ["synonymous (dS) substitution rates", "TREATMENT", 165, 199], ["pressure", "OBSERVATION_MODIFIER", 49, 57]]], ["MEME is used to detect positive selection sites under a proportion of branches.", [["positive selection sites", "PROBLEM", 23, 47], ["branches", "ANATOMY_MODIFIER", 70, 78]]], ["Significance levels were set at posterior probabilities of >0.9 for FUBAR and p < 0.05 for MEME.Median Joining Network Analyses ::: Materials and MethodsTransmission links between GII.P17-GII.17 strains were analyzed using a median joining network with PopART software (Bandelt et al., 1999; Leigh and Bryant, 2015).", [["P17-GII", "GENE_OR_GENE_PRODUCT", 184, 191], ["P17", "PROTEIN", 184, 187], ["Significance levels", "TEST", 0, 19], ["posterior probabilities", "TEST", 32, 55], ["FUBAR", "TEST", 68, 73]]], ["We constructed a dataset that covered nucleotide sequence lengths from the start position of RdRp to the terminal position of VP1 (resulting in a total of 114 strains).", [["nucleotide", "CHEMICAL", 38, 48], ["nucleotide", "CHEMICAL", 38, 48], ["VP1", "GENE_OR_GENE_PRODUCT", 126, 129], ["RdRp", "PROTEIN", 93, 97], ["VP1", "DNA", 126, 129], ["nucleotide sequence lengths", "TREATMENT", 38, 65], ["RdRp", "TREATMENT", 93, 97], ["VP1", "TEST", 126, 129], ["terminal", "OBSERVATION_MODIFIER", 105, 113], ["position", "OBSERVATION_MODIFIER", 114, 122]]], ["The dataset was then processed to detect recombination between the RdRp and VP1 sequences based on seven primary exploratory recombination signal detection methods (RDP, GENECONV, BootScan, MaxChi, Chimera, SiScan, and 3Seq) using RDP4 software (Martin et al., 2015) and the threshold of the p-value for significance was set at 0.001.", [["RdRp and VP1 sequences", "DNA", 67, 89], ["the RdRp and VP1 sequences", "TEST", 63, 89]]], ["Recombination regions were assigned when they were identified by more than four of the seven methods; however, this criterion resulted in the identification of no recombinant sequences in the dataset.", [["recombinant sequences", "DNA", 163, 184]]], ["The median joining networks were analyzed using an epsilon value of zero.Time-Scaled Phylogeny of the VP1 and RdRp Regions in the GII.P17-GII.17 Strains ::: ResultsWe constructed time-scaled phylogenetic trees using the MCMC method based on the full-length of the VP1 (343 strains) and RdRp (133 strains) regions in the GII.17 strains detected in the various countries (Figures 1, 2).", [["VP1", "GENE_OR_GENE_PRODUCT", 102, 105], ["P17-GII", "GENE_OR_GENE_PRODUCT", 134, 141], ["VP1 and RdRp Regions", "DNA", 102, 122], ["P17", "PROTEIN", 134, 137], ["RdRp (133 strains) regions", "DNA", 286, 312], ["an epsilon value", "TEST", 48, 64], ["the MCMC method", "TREATMENT", 216, 231], ["the VP1", "TEST", 260, 267], ["RdRp (133 strains) regions in the GII", "PROBLEM", 286, 323], ["17 strains", "PROBLEM", 324, 334], ["VP1", "ANATOMY", 102, 105], ["RdRp", "ANATOMY_MODIFIER", 110, 114], ["Regions", "ANATOMY_MODIFIER", 115, 122], ["GII", "ANATOMY", 130, 133], ["GII", "ANATOMY", 320, 323]]], ["The MCMC tree for the VP1 region estimated that the common ancestor of the GII.17, GII.13, and GII.21 diverged in September, 1931 (95% HPD January, 1911\u2013February, 1950).", [["MCMC tree", "MULTI-TISSUE_STRUCTURE", 4, 13], ["VP1 region", "DNA", 22, 32], ["the VP1 region", "PROBLEM", 18, 32], ["the GII", "TEST", 71, 78], ["GII", "TEST", 83, 86]]], ["A common ancestor of the GII.17 strains diverged in November, 1948 (95% HPD September, 1934\u2013November, 1961) and further diverged into seven clusters by around October, 2011.", [["GII", "OBSERVATION", 25, 28]]], ["Of these, the GII.P17-GII.17 strains belonged to clusters 1 and 2 (Figure 1).", [["P17-GII", "GENE_OR_GENE_PRODUCT", 18, 25], ["P17", "PROTEIN", 18, 21]]], ["The GII.17 strains in clusters 3, 4, 5, and 6 (no information on the RdRp sequence in cluster 7) were composed of the distinct RdRp genotypes, including GII.P3, GII.P16, GII.P4, and GII.Pe, respectively (Figure 1 and Table S1).", [["P16", "GENE_OR_GENE_PRODUCT", 165, 168], ["GII", "GENE_OR_GENE_PRODUCT", 170, 173], ["RdRp sequence", "DNA", 69, 82], ["P16", "PROTEIN", 165, 168], ["17 strains in clusters", "PROBLEM", 8, 30], ["the RdRp sequence", "TEST", 65, 82], ["P16", "TEST", 165, 168], ["P4", "PROBLEM", 174, 176], ["Pe", "PROBLEM", 186, 188], ["GII", "OBSERVATION", 4, 7], ["RdRp genotypes", "OBSERVATION", 127, 141], ["GII", "OBSERVATION", 161, 164]]], ["Most strains of the GII.P17-GII.17 belonged to the cluster 1 (the Kawasaki308 type).", [["P17-GII", "GENE_OR_GENE_PRODUCT", 24, 31], ["P17", "PROTEIN", 24, 27]]], ["Moreover, analyses of phylogenetic distances exhibited no overlap between intra- and inter-cluster peaks at a value of 0.035 (Figure 3A).", [["phylogenetic distances", "PROBLEM", 22, 44], ["overlap between intra- and inter-cluster peaks", "PROBLEM", 58, 104], ["intra", "ANATOMY_MODIFIER", 74, 79]]], ["With respect to the RdRp region (Figure 2), the common ancestor of the GII.P17 and GII.P3 diverged in January, 1988 (95% HPD December, 1980\u2013May, 1993).", [["P17", "GENE_OR_GENE_PRODUCT", 75, 78], ["GII", "GENE_OR_GENE_PRODUCT", 83, 86], ["RdRp region", "DNA", 20, 31], ["P3", "DNA", 87, 89], ["RdRp", "OBSERVATION", 20, 24], ["GII", "ANATOMY", 71, 74]]], ["Subsequently, the common ancestor of the GII.P17 diverged in October, 2009 (95% HPD May, 2006\u2013April, 2012) and then further into two clusters by around August, 2012.", [["GII", "ANATOMY", 41, 44]]], ["The GII.P17-GII.17 strains were contained in clusters 1 and 2 in the RdRp region, which was compatible with the classification in the VP1 region.", [["P17", "GENE_OR_GENE_PRODUCT", 8, 11], ["RdRp region", "DNA", 69, 80], ["VP1 region", "DNA", 134, 144], ["P17", "TEST", 8, 11], ["strains", "PROBLEM", 19, 26], ["the classification in the VP1 region", "PROBLEM", 108, 144], ["GII", "OBSERVATION", 4, 7], ["RdRp", "ANATOMY_MODIFIER", 69, 73], ["region", "ANATOMY_MODIFIER", 74, 80], ["compatible with", "UNCERTAINTY", 92, 107], ["VP1", "ANATOMY", 134, 137], ["region", "ANATOMY_MODIFIER", 138, 144]]], ["Most strains of the GII.P17-GII.17 also belonged to cluster 1 (the Kawasaki308 type).", [["P17-GII", "GENE_OR_GENE_PRODUCT", 24, 31], ["P17", "PROTEIN", 24, 27]]], ["Furthermore, phylogenetic distances overlapped between the intra- and inter-cluster peaks (Figure 3B).", [["phylogenetic distances", "PROBLEM", 13, 35], ["phylogenetic distances", "OBSERVATION", 13, 35], ["intra", "ANATOMY_MODIFIER", 59, 64]]], ["These results suggest that the GII.P17-GII.17 strains emerged and formed two variants in approximately the past 10 years.Evolutionary Rates of the VP1 and RdRp Regions in the GII.P17-GII.17 Strains ::: ResultsThe evolutionary rates of the VP1 and RdRp regions of the GII.P17-GII.17 strains are presented in Table 1.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 35, 42], ["VP1", "GENE_OR_GENE_PRODUCT", 147, 150], ["P17-GII", "GENE_OR_GENE_PRODUCT", 179, 186], ["VP1", "GENE_OR_GENE_PRODUCT", 239, 242], ["P17-GII", "GENE_OR_GENE_PRODUCT", 271, 278], ["P17", "PROTEIN", 35, 38], ["VP1 and RdRp Regions", "DNA", 147, 167], ["P17", "PROTEIN", 179, 182], ["VP1 and RdRp regions", "DNA", 239, 259], ["P17", "PROTEIN", 271, 274], ["the GII", "PROBLEM", 27, 34], ["Evolutionary Rates", "TEST", 121, 139], ["the VP1 and RdRp Regions in the GII", "PROBLEM", 143, 178], ["the VP1 and RdRp regions of the GII", "PROBLEM", 235, 270], ["VP1", "ANATOMY", 147, 150], ["RdRp", "OBSERVATION_MODIFIER", 155, 159], ["GII", "ANATOMY", 175, 178], ["VP1", "ANATOMY", 239, 242], ["GII", "ANATOMY", 267, 270]]], ["The rate for the VP1 region was 2.7 \u00d7 10\u22123 substitutions/site/year (95% HPD 2.2\u20133.2 \u00d7 10\u22123), while that for the RdRp region was 2.3 \u00d7 10\u22123 (95% HPD 1.5\u20133.2 \u00d7 10\u22123).", [["VP1 region", "DNA", 17, 27], ["RdRp region", "DNA", 112, 123], ["The rate", "TEST", 0, 8], ["the VP1 region", "TEST", 13, 27], ["HPD", "TEST", 72, 75], ["the RdRp region", "TEST", 108, 123], ["HPD", "TEST", 144, 147]]], ["These results indicate that the VP1 and RdRp regions of the GII.P17-GII.17 strains evolved with similar rates.Phylodynamics of GII.P17-GII.17 Strains in the VP1 Region ::: ResultsWe estimated the transition of population sizes of GII.P17-GII.17 in the VP1 region using a Bayesian skyline plot.", [["VP1", "GENE_OR_GENE_PRODUCT", 32, 35], ["P17-GII", "GENE_OR_GENE_PRODUCT", 64, 71], ["P17-GII", "GENE_OR_GENE_PRODUCT", 131, 138], ["P17-GII", "GENE_OR_GENE_PRODUCT", 234, 241], ["VP1 and RdRp regions", "DNA", 32, 52], ["P17", "PROTEIN", 64, 67], ["P17", "PROTEIN", 131, 134], ["P17", "PROTEIN", 234, 237], ["VP1 region", "DNA", 252, 262], ["the VP1 and RdRp regions of the GII", "PROBLEM", 28, 63], ["GII", "PROBLEM", 230, 233], ["a Bayesian skyline plot", "TEST", 269, 292], ["VP1", "OBSERVATION", 32, 35], ["RdRp", "OBSERVATION_MODIFIER", 40, 44], ["GII", "ANATOMY", 60, 63], ["sizes", "OBSERVATION_MODIFIER", 221, 226], ["VP1", "ANATOMY", 252, 255], ["region", "ANATOMY_MODIFIER", 256, 262]]], ["The population of this region increased sharply in around 2014 and remained constant from 2016 after an immediate reduction (Figure 4).", [["an immediate reduction", "TREATMENT", 101, 123], ["population", "OBSERVATION_MODIFIER", 4, 14], ["region", "OBSERVATION_MODIFIER", 23, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["sharply", "OBSERVATION_MODIFIER", 40, 47]]], ["These results suggest that this was compatible between the fluctuation of the plot and actually epidemiological GII.17 prevalence.Prediction of Conformational Epitopes and Selective Pressures in the VP1 in GII.P17-GII.17 Strains ::: ResultsConformational epitopes and selective pressures in the VP1 protein were analyzed in order to assess the possibility of antigenicity changes at pre and post emergence of GII.P17-GII.17 based on the time-scaled phylogeny for the VP1 region in Figure 1.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 210, 217], ["VP1", "GENE_OR_GENE_PRODUCT", 295, 298], ["P17-GII", "GENE_OR_GENE_PRODUCT", 413, 420], ["VP1", "PROTEIN", 199, 202], ["P17", "PROTEIN", 210, 213], ["VP1 protein", "PROTEIN", 295, 306], ["P17", "PROTEIN", 413, 416], ["VP1 region", "DNA", 467, 477], ["the fluctuation of the plot", "PROBLEM", 55, 82], ["Conformational Epitopes", "TREATMENT", 144, 167], ["Selective Pressures", "TEST", 172, 191], ["the VP1 in GII", "TREATMENT", 195, 209], ["selective pressures", "TEST", 268, 287], ["the VP1 protein", "TEST", 291, 306], ["antigenicity changes", "PROBLEM", 359, 379], ["GII", "PROBLEM", 409, 412], ["the VP1 region", "PROBLEM", 463, 477], ["Conformational Epitopes", "OBSERVATION", 144, 167], ["Selective", "OBSERVATION_MODIFIER", 172, 181], ["Pressures", "OBSERVATION_MODIFIER", 182, 191], ["VP1", "ANATOMY", 199, 202], ["selective", "OBSERVATION_MODIFIER", 268, 277], ["pressures", "OBSERVATION_MODIFIER", 278, 287], ["VP1 protein", "ANATOMY", 295, 306], ["antigenicity", "OBSERVATION", 359, 371]]], ["As a result, common epitopes among strains of clusters 1, 2 (GII.P17-GII.17 clusters) and 3 [a closely related cluster (GII.P3-GII.17 strain) to the GII.P17-GII.17 clusters] were found in the shell domain and the protruding 2 (P2) domain.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 65, 72], ["P17-GII", "GENE_OR_GENE_PRODUCT", 153, 160], ["P17", "PROTEIN", 65, 68], ["P17", "PROTEIN", 153, 156], ["shell domain", "PROTEIN", 192, 204], ["protruding 2 (P2) domain", "PROTEIN", 213, 237], ["a closely related cluster (GII", "PROBLEM", 93, 123], ["P3", "TEST", 124, 126], ["GII", "ANATOMY", 149, 152], ["shell", "ANATOMY_MODIFIER", 192, 197], ["protruding", "OBSERVATION", 213, 223]]], ["Although the amino acid epitope positions were similar among the strains, many amino acid substitutions were identified (Figure 5 and Table 2).", [["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 79, 89], ["amino acid", "AMINO_ACID", 13, 23], ["amino acid", "AMINO_ACID", 79, 89], ["the amino acid epitope positions", "TREATMENT", 9, 41], ["the strains", "PROBLEM", 61, 72], ["many amino acid substitutions", "PROBLEM", 74, 103], ["amino", "OBSERVATION", 79, 84], ["acid substitutions", "OBSERVATION", 85, 103]]], ["Substitutions in epitopes were also identified in strains belonging to the same cluster.", [["epitopes", "PROTEIN", 17, 25], ["Substitutions in epitopes", "PROBLEM", 0, 25], ["strains", "PROBLEM", 50, 57]]], ["Of these substitution residues, amino acids (aa) 375, aa376, aa394, aa396, and aa442 are located close to the histo-blood group antigen (HBGA) binding sites of VP1, which are utilized for attachment of HuNoV to host cells.", [["cells", "ANATOMY", 216, 221], ["amino acids", "CHEMICAL", 32, 43], ["amino acids", "CHEMICAL", 32, 43], ["amino acids", "AMINO_ACID", 32, 43], ["aa) 375", "AMINO_ACID", 45, 52], ["aa376", "GENE_OR_GENE_PRODUCT", 54, 59], ["aa394", "GENE_OR_GENE_PRODUCT", 61, 66], ["aa396", "GENE_OR_GENE_PRODUCT", 68, 73], ["aa442", "GENE_OR_GENE_PRODUCT", 79, 84], ["histo-blood group antigen", "GENE_OR_GENE_PRODUCT", 110, 135], ["HBGA", "GENE_OR_GENE_PRODUCT", 137, 141], ["VP1", "GENE_OR_GENE_PRODUCT", 160, 163], ["HuNoV", "GENE_OR_GENE_PRODUCT", 202, 207], ["host cells", "CELL", 211, 221], ["aa442", "PROTEIN", 79, 84], ["histo-blood group antigen (HBGA) binding sites", "DNA", 110, 156], ["VP1", "PROTEIN", 160, 163], ["HuNoV", "PROTEIN", 202, 207], ["host cells", "CELL_TYPE", 211, 221], ["these substitution residues", "TREATMENT", 3, 30], ["amino acids (aa)", "TEST", 32, 48], ["binding sites of VP1", "PROBLEM", 143, 163], ["substitution residues", "OBSERVATION", 9, 30], ["host cells", "OBSERVATION", 211, 221]]], ["Additionally, three positive selection sites were identified in the P2 domain (Asn342Ser, Glu376Asn/Asp, and Arg412Leu/Glu/Pro).", [["Asp", "CHEMICAL", 100, 103], ["Arg", "CHEMICAL", 109, 112], ["Glu", "CHEMICAL", 119, 122], ["P2 domain", "DNA", 68, 77], ["three positive selection sites", "PROBLEM", 14, 44], ["the P2 domain", "TEST", 64, 77], ["Asn342Ser", "TEST", 79, 88], ["Glu376Asn", "TEST", 90, 99], ["Asp", "TEST", 100, 103], ["Arg", "TEST", 109, 112]]], ["Of these sites, aa342 and aa376 were at predicted epitopes (Figure 5).", [["aa342", "GENE_OR_GENE_PRODUCT", 16, 21], ["aa376", "GENE_OR_GENE_PRODUCT", 26, 31], ["aa342", "DNA", 16, 21], ["aa376", "DNA", 26, 31], ["sites", "OBSERVATION_MODIFIER", 9, 14]]], ["These results indicate that GII.P17-GII.17 could evolve with changes in antigenicity and binding affinity to HBGAs.Mapping of Amino Acid Substitutions of GII.P17-GII.17 to the RdRp Protein ::: ResultsTo assess the possibility of changes of RNA replication properties at pre and post emergence of GII.P17-GII.17 based on the time-scaled phylogeny for the RdRp region in Figure 2, we mapped the amino acid substitutions between GII.P17 strains and other RdRp genotypes onto three-dimensional structures of the RdRp protein (Figure 6).", [["Amino Acid", "CHEMICAL", 126, 136], ["amino acid", "CHEMICAL", 393, 403], ["Amino Acid", "CHEMICAL", 126, 136], ["amino acid", "CHEMICAL", 393, 403], ["P17-GII", "GENE_OR_GENE_PRODUCT", 32, 39], ["HBGAs", "SIMPLE_CHEMICAL", 109, 114], ["Amino Acid", "SIMPLE_CHEMICAL", 126, 136], ["P17", "GENE_OR_GENE_PRODUCT", 158, 161], ["P17-GII", "GENE_OR_GENE_PRODUCT", 300, 307], ["amino acid", "AMINO_ACID", 393, 403], ["P17", "GENE_OR_GENE_PRODUCT", 430, 433], ["P17", "PROTEIN", 32, 35], ["P17", "PROTEIN", 158, 161], ["GII.17", "PROTEIN", 162, 168], ["RdRp Protein", "PROTEIN", 176, 188], ["P17", "PROTEIN", 300, 303], ["RdRp region", "DNA", 354, 365], ["RdRp protein", "PROTEIN", 508, 520], ["Figure 6", "PROTEIN", 522, 530], ["GII", "PROBLEM", 28, 31], ["changes in antigenicity", "PROBLEM", 61, 84], ["HBGAs", "TEST", 109, 114], ["Amino Acid Substitutions of GII", "TREATMENT", 126, 157], ["P17", "TEST", 158, 161], ["RNA replication properties", "TREATMENT", 240, 266], ["GII", "PROBLEM", 296, 299], ["the amino acid substitutions between GII", "TREATMENT", 389, 429], ["P17 strains", "PROBLEM", 430, 441], ["other RdRp genotypes", "TREATMENT", 446, 466], ["GII", "OBSERVATION", 28, 31], ["Amino Acid", "OBSERVATION", 126, 136], ["RdRp", "OBSERVATION_MODIFIER", 452, 456], ["RdRp protein", "OBSERVATION", 508, 520]]], ["A total of 48 amino acid substitutions were identified among the GII.P17 and GII.P4 strains (Accession number; FJ537137).", [["amino acid", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["P17", "GENE_OR_GENE_PRODUCT", 69, 72], ["GII", "GENE_OR_GENE_PRODUCT", 77, 80], ["A total of 48 amino acid substitutions", "TREATMENT", 0, 38]]], ["Of these, the substitutions at aa33, aa34, aa49, and aa434 were located close to the interface between monomers, while substitutions at aa206, aa215, aa409, aa438, and aa442 were located close to the active site (Figure 6A).", [["aa33", "GENE_OR_GENE_PRODUCT", 31, 35], ["aa34", "GENE_OR_GENE_PRODUCT", 37, 41], ["aa49", "GENE_OR_GENE_PRODUCT", 43, 47], ["aa434", "GENE_OR_GENE_PRODUCT", 53, 58], ["aa206", "GENE_OR_GENE_PRODUCT", 136, 141], ["aa215", "GENE_OR_GENE_PRODUCT", 143, 148], ["aa409", "GENE_OR_GENE_PRODUCT", 150, 155], ["aa438", "GENE_OR_GENE_PRODUCT", 157, 162], ["aa442", "GENE_OR_GENE_PRODUCT", 168, 173], ["aa33, aa34, aa49, and aa434", "DNA", 31, 58], ["aa206, aa215, aa409, aa438, and aa442", "DNA", 136, 173], ["active site", "DNA", 200, 211], ["the substitutions", "PROBLEM", 10, 27], ["aa34", "TEST", 37, 41], ["active", "OBSERVATION_MODIFIER", 200, 206]]], ["Moreover, a total of 16 amino acid substitutions were estimated among the GII.P17 and GII.P3 (a closely related genotype to GII.P17) strains (Accession number; KJ194500).", [["amino acid", "CHEMICAL", 24, 34], ["amino acid", "CHEMICAL", 24, 34], ["amino acid", "AMINO_ACID", 24, 34], ["P17", "GENE_OR_GENE_PRODUCT", 78, 81], ["GII", "GENE_OR_GENE_PRODUCT", 86, 89], ["P3", "GENE_OR_GENE_PRODUCT", 90, 92], ["P17", "GENE_OR_GENE_PRODUCT", 128, 131], ["P3", "DNA", 90, 92], ["a total of 16 amino acid substitutions", "TREATMENT", 10, 48], ["P3", "PROBLEM", 90, 92]]], ["The substitution at aa49 was located adjacent to the interface between monomers, whereas the substitutions at aa206, aa215, aa407, and aa409 were located proximal to the active site (Figure S1).", [["aa49", "GENE_OR_GENE_PRODUCT", 20, 24], ["aa206", "GENE_OR_GENE_PRODUCT", 110, 115], ["aa215", "GENE_OR_GENE_PRODUCT", 117, 122], ["aa407", "GENE_OR_GENE_PRODUCT", 124, 129], ["aa409", "GENE_OR_GENE_PRODUCT", 135, 140], ["aa49", "PROTEIN", 20, 24], ["aa206, aa215, aa407, and aa409", "DNA", 110, 140], ["active site", "DNA", 170, 181], ["Figure S1", "DNA", 183, 192], ["The substitution at aa49", "TREATMENT", 0, 24], ["the substitutions", "PROBLEM", 89, 106], ["substitution", "OBSERVATION_MODIFIER", 4, 16], ["monomers", "OBSERVATION_MODIFIER", 71, 79], ["substitutions", "OBSERVATION_MODIFIER", 93, 106], ["active", "OBSERVATION_MODIFIER", 170, 176], ["site", "OBSERVATION_MODIFIER", 177, 181]]], ["For intra-GII.P17 genotype, Phe206Leu and Lys405Arg substitutions were found around the active site in the strains of cluster 2 (12 strains) (Figure 6B).", [["Arg", "CHEMICAL", 48, 51], ["P17", "GENE_OR_GENE_PRODUCT", 14, 17], ["Phe206Leu", "GENE_OR_GENE_PRODUCT", 28, 37], ["Lys405", "AMINO_ACID", 42, 48], ["Arg", "AMINO_ACID", 48, 51], ["intra-GII", "PROTEIN", 4, 13], ["intra-GII", "PROBLEM", 4, 13], ["P17 genotype", "TEST", 14, 26], ["Phe206Leu", "TEST", 28, 37], ["Lys405Arg substitutions", "TREATMENT", 42, 65], ["active", "OBSERVATION_MODIFIER", 88, 94], ["site", "OBSERVATION_MODIFIER", 95, 99]]], ["Thirty one substitutions were also found in the strains belonging to the cluster 1 (121 strains), and a Ser427Asn substitution was located proximally at the interface between monomers.", [["Ser427Asn", "GENE_OR_GENE_PRODUCT", 104, 113], ["the strains", "PROBLEM", 44, 55], ["a Ser427Asn substitution", "TREATMENT", 102, 126]]], ["Ile193Val, Ile215Val, Asp224Glu, Ile346Val, Thr394Ala, Val395Ile, Asn409Ser, Val438Met, Gly445Ser, and Phe503Leu substitutions were located close to the active sites (Figure 6C).Transmission Network Between the GII.P17-GII.17 Strains ::: ResultsLinks in circulation of prevalent GII.P17-GII.17 (cluster 1) in Japanese regions and in other countries were analyzed using a median joining network.", [["Ile", "CHEMICAL", 0, 3], ["Ile", "CHEMICAL", 11, 14], ["Asp", "CHEMICAL", 22, 25], ["Thr", "CHEMICAL", 44, 47], ["Val", "CHEMICAL", 55, 58], ["Asn", "CHEMICAL", 66, 69], ["Val", "CHEMICAL", 77, 80], ["Gly", "CHEMICAL", 88, 91], ["Phe503Leu", "CHEMICAL", 103, 112], ["Ile", "AMINO_ACID", 0, 3], ["Ile215Val", "AMINO_ACID", 11, 20], ["Asp224Glu", "AMINO_ACID", 22, 31], ["Thr394Ala", "AMINO_ACID", 44, 53], ["Val395Ile", "AMINO_ACID", 55, 64], ["Asn409Ser", "AMINO_ACID", 66, 75], ["Gly", "AMINO_ACID", 88, 91], ["445Ser", "AMINO_ACID", 91, 97], ["Phe503Leu", "AMINO_ACID", 103, 112], ["P17", "GENE_OR_GENE_PRODUCT", 215, 218], ["P17", "GENE_OR_GENE_PRODUCT", 283, 286], ["GII.17", "DNA", 287, 293], ["Asp", "TEST", 22, 25], ["Phe503Leu substitutions", "TREATMENT", 103, 126], ["P17", "TEST", 215, 218], ["P17", "TEST", 283, 286], ["a median joining network", "TREATMENT", 369, 393], ["circulation", "OBSERVATION_MODIFIER", 254, 265]]], ["The strains analyzed in this study were divided into four clusters.", [["The strains", "PROBLEM", 0, 11], ["this study", "TEST", 24, 34]]], ["The strains in cluster 4 were detected only in Miyagi prefecture in Japan.", [["The strains in cluster 4", "PROBLEM", 0, 24], ["strains", "OBSERVATION_MODIFIER", 4, 11]]], ["Notably, the network contained the key strains that were linked to the many other strains (Figure 7).", [["the key strains", "PROBLEM", 31, 46]]], ["These results suggest that the GII.P17-GII.17 strains form a broad network and that some strains are associated with the prevalence of the virus.DiscussionIn this study, we demonstrated the molecular evolution of both the VP1 and RdRp regions of GII.P17-GII.17 since the emergence of the virus.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 35, 42], ["VP1", "GENE_OR_GENE_PRODUCT", 222, 225], ["P17-GII", "GENE_OR_GENE_PRODUCT", 250, 257], ["P17", "PROTEIN", 35, 38], ["VP1 and RdRp regions", "DNA", 222, 242], ["P17", "PROTEIN", 250, 253], ["the GII", "PROBLEM", 27, 34], ["a broad network", "PROBLEM", 59, 74], ["some strains", "PROBLEM", 84, 96], ["the virus", "PROBLEM", 135, 144], ["this study", "TEST", 158, 168], ["the VP1 and RdRp regions of GII", "PROBLEM", 218, 249], ["the virus", "PROBLEM", 284, 293], ["virus", "OBSERVATION", 139, 144], ["VP1", "ANATOMY", 222, 225], ["GII", "ANATOMY", 246, 249], ["virus", "OBSERVATION", 288, 293]]], ["First, a MCMC time-scaled evolutionary phylogenetic tree based on GII.17 VP1 nucleotide sequences showed that all the present strains grouped into a total of seven clusters (Figure 1).", [["nucleotide", "CHEMICAL", 77, 87], ["17 VP1 nucleotide sequences", "DNA", 70, 97], ["a MCMC time", "TEST", 7, 18], ["VP1 nucleotide sequences", "TEST", 73, 97], ["all the present strains", "PROBLEM", 110, 133], ["phylogenetic tree", "OBSERVATION", 39, 56]]], ["Trees also indicated that the recently emerged GII.P17-GII.17 strains uniquely formed 2 clusters (clusters 1 and 2) based on both the VP1 and RdRp regions.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 51, 58], ["VP1", "GENE_OR_GENE_PRODUCT", 134, 137], ["P17", "PROTEIN", 51, 54], ["VP1 and RdRp regions", "DNA", 134, 154], ["VP1", "ANATOMY", 134, 137], ["RdRp", "ANATOMY_MODIFIER", 142, 146], ["regions", "ANATOMY_MODIFIER", 147, 154]]], ["The common ancestor of the VP1 region of the GII.P17-GII.17 viruses diverged first, followed by divergence of the RdRp region after a several-year delay (Figures 1, 2).", [["P17-GII", "GENE_OR_GENE_PRODUCT", 49, 56], ["VP1 region", "DNA", 27, 37], ["P17", "PROTEIN", 49, 52], ["RdRp region", "DNA", 114, 125], ["17 viruses", "PROBLEM", 57, 67], ["common", "ANATOMY_MODIFIER", 4, 10], ["ancestor", "ANATOMY_MODIFIER", 11, 19], ["VP1", "ANATOMY_MODIFIER", 27, 30], ["region", "ANATOMY_MODIFIER", 31, 37], ["GII", "ANATOMY", 45, 48], ["viruses", "OBSERVATION", 60, 67], ["RdRp", "OBSERVATION", 114, 118]]], ["Previous reports have also suggested a gap in the divergence of GII.P16-GII.2 strains (Mizukoshi et al., 2017; Nagasawa et al., 2018).", [["P16", "GENE_OR_GENE_PRODUCT", 68, 71], ["a gap", "PROBLEM", 37, 42], ["GII", "PROBLEM", 64, 67], ["P16", "TEST", 68, 71]]], ["To resolve this issue, we analyzed the phylogenetic distances of the VP1 and RdRp regions and found that the distance of the VP1 region was longer than that of RdRp, indicating that the genetic diversity of VP1 in GII.P17-GII.17 is larger than that of RdRp (Figure 3).", [["VP1", "GENE_OR_GENE_PRODUCT", 69, 72], ["VP1", "GENE_OR_GENE_PRODUCT", 125, 128], ["VP1", "ORGANISM", 207, 210], ["P17-GII", "GENE_OR_GENE_PRODUCT", 218, 225], ["VP1 and RdRp regions", "DNA", 69, 89], ["VP1 region", "DNA", 125, 135], ["RdRp", "PROTEIN", 160, 164], ["VP1", "DNA", 207, 210], ["P17", "PROTEIN", 218, 221], ["RdRp", "PROTEIN", 252, 256], ["RdRp", "PROBLEM", 160, 164], ["VP1 in GII", "PROBLEM", 207, 217], ["VP1", "ANATOMY", 69, 72], ["VP1 region", "ANATOMY", 125, 135], ["larger", "OBSERVATION_MODIFIER", 232, 238]]], ["However, the evolutionary rates for the overall cluster in GII.P17-GII.17 were similar between the VP1 and RdRp regions (Table 1).", [["P17-GII", "GENE_OR_GENE_PRODUCT", 63, 70], ["P17", "PROTEIN", 63, 66], ["VP1 and RdRp regions", "DNA", 99, 119], ["VP1", "ANATOMY", 99, 102], ["RdRp", "ANATOMY_MODIFIER", 107, 111], ["regions", "ANATOMY_MODIFIER", 112, 119]]], ["Thus, we also calculated the rates of the strains belonging to the cluster 1, which resulted in reduction of the value in the RdRp region, but not in the VP1 region (data not shown).", [["cluster 1", "DNA", 67, 76], ["RdRp region", "DNA", 126, 137], ["VP1 region", "DNA", 154, 164], ["the strains", "PROBLEM", 38, 49], ["reduction", "OBSERVATION_MODIFIER", 96, 105], ["RdRp", "ANATOMY_MODIFIER", 126, 130], ["region", "ANATOMY_MODIFIER", 131, 137], ["VP1 region", "ANATOMY", 154, 164]]], ["Furthermore, we analyzed the time-scaled MCMC phylogenetic trees by adding 343 sequences of GII.17 for the VP1, 133 sequences of GII.P17 for the RdRp and data of not only collection years but also months, which produced confidence intervals (95% HPD values) that were smaller in our analyses than in an earlier report (Sang and Yang, 2018).", [["P17", "GENE_OR_GENE_PRODUCT", 133, 136], ["VP1", "DNA", 107, 110], ["P17", "PROTEIN", 133, 136], ["RdRp", "PROTEIN", 145, 149], ["the VP1", "TEST", 103, 110], ["the RdRp", "PROBLEM", 141, 149], ["HPD values", "TEST", 246, 256], ["smaller", "OBSERVATION_MODIFIER", 268, 275]]], ["Thus, more precise collection data, as well as the use of a large number of virus strains, may facilitate the construction of more precise MCMC phylogeny.DiscussionThe evolutionary rates of the VP1 and RdRp regions in the GII.P17-GII.17 were ~2.7 and ~2.3 \u00d7 10\u22123 substitutions/site/year, respectively (Table 1).", [["VP1", "GENE_OR_GENE_PRODUCT", 194, 197], ["P17-GII", "GENE_OR_GENE_PRODUCT", 226, 233], ["VP1 and RdRp regions", "DNA", 194, 214], ["P17", "PROTEIN", 226, 229], ["virus strains", "TREATMENT", 76, 89], ["the VP1 and RdRp regions in the GII", "PROBLEM", 190, 225], ["large", "OBSERVATION_MODIFIER", 60, 65], ["VP1", "ANATOMY", 194, 197], ["GII", "ANATOMY", 222, 225]]], ["The rate for GII.17 is likely similar to that for GII.2 in the VP1 region, but lower than that of GII.4 (Bok et al., 2009; Siebenga et al., 2010; Mizukoshi et al., 2017; Motoya et al., 2017).", [["GII.2", "PROTEIN", 50, 55], ["VP1 region", "DNA", 63, 73], ["GII", "PROBLEM", 13, 16], ["likely", "UNCERTAINTY", 23, 29], ["similar", "OBSERVATION_MODIFIER", 30, 37], ["VP1", "ANATOMY", 63, 66], ["region", "ANATOMY_MODIFIER", 67, 73], ["lower", "OBSERVATION_MODIFIER", 79, 84]]], ["Furthermore, the rate for GII.P17 is likely analogous to that for GII.P16, but lower than that of GII.P4 (Nagasawa et al., 2018; Ozaki et al., 2018).", [["P17", "GENE_OR_GENE_PRODUCT", 30, 33], ["P16", "GENE_OR_GENE_PRODUCT", 70, 73], ["P16", "PROTEIN", 70, 73], ["GII", "PROBLEM", 26, 29], ["GII", "PROBLEM", 66, 69], ["P16", "TEST", 70, 73], ["lower", "OBSERVATION_MODIFIER", 79, 84]]], ["Interestingly, it has been suggested that GII.P4-GII.4 virus prevalence is associated with the rapid evolution of the VP1 regions with a high ratio of non-synonymous amino acid substitutions to synonymous substitutions (Bull et al., 2010; Parra et al., 2017).", [["amino acid", "CHEMICAL", 166, 176], ["amino acid", "CHEMICAL", 166, 176], ["P4-GII.4 virus", "ORGANISM", 46, 60], ["amino acid", "AMINO_ACID", 166, 176], ["VP1 regions", "DNA", 118, 129], ["GII.4 virus", "SPECIES", 49, 60], ["GII", "PROBLEM", 42, 45], ["P4", "PROBLEM", 46, 48], ["GII.4 virus prevalence", "PROBLEM", 49, 71], ["the VP1 regions", "PROBLEM", 114, 129], ["non-synonymous amino acid substitutions", "PROBLEM", 151, 190], ["synonymous substitutions", "PROBLEM", 194, 218], ["rapid", "OBSERVATION_MODIFIER", 95, 100], ["VP1 regions", "ANATOMY", 118, 129], ["high", "OBSERVATION_MODIFIER", 137, 141], ["amino acid substitutions", "OBSERVATION", 166, 190], ["synonymous substitutions", "OBSERVATION", 194, 218]]], ["Previous reports have also suggested that the rates of non-synonymous amino substitutions in the VP1 protein differ between GII.17 and GII.4, with GII.4 being greater than GII.17 (Mori et al., 2017); therefore, the rates of antigenicity change between GII.17 and GII.4 viruses may be distinct.", [["amino", "CHEMICAL", 70, 75], ["amino", "AMINO_ACID", 70, 75], ["VP1", "GENE_OR_GENE_PRODUCT", 97, 100], ["VP1 protein", "PROTEIN", 97, 108], ["non-synonymous amino substitutions", "PROBLEM", 55, 89], ["the VP1 protein", "TEST", 93, 108], ["GII", "TEST", 135, 138], ["viruses", "OBSERVATION", 269, 276], ["may be", "UNCERTAINTY", 277, 283], ["distinct", "OBSERVATION_MODIFIER", 284, 292]]], ["In contrast, it has been estimated that the number of negative selection sites in GII.P4 RdRp are larger than that in GII.P17 (Ozaki et al., 2018), and thus variations in nucleotide substitution in GII.P4 RdRp may be restricted compared to GII.P17.", [["nucleotide", "CHEMICAL", 171, 181], ["nucleotide", "CHEMICAL", 171, 181], ["P4", "GENE_OR_GENE_PRODUCT", 86, 88], ["P4", "GENE_OR_GENE_PRODUCT", 202, 204], ["P17", "GENE_OR_GENE_PRODUCT", 244, 247], ["P4 RdRp", "PROTEIN", 86, 93], ["P17", "PROTEIN", 244, 247], ["P4 RdRp", "TREATMENT", 86, 93], ["variations in nucleotide substitution in GII", "PROBLEM", 157, 201], ["P4 RdRp", "TREATMENT", 202, 209], ["negative selection sites", "OBSERVATION", 54, 78], ["larger", "OBSERVATION_MODIFIER", 98, 104], ["nucleotide substitution", "OBSERVATION", 171, 194]]], ["However, despite such restrictions, we observed a lower evolutionary rate in GII.P17 than GII.P4.", [["P17", "GENE_OR_GENE_PRODUCT", 81, 84], ["a lower evolutionary rate in GII", "PROBLEM", 48, 80], ["P4", "PROBLEM", 94, 96]]], ["This may be due to differences in replication activities and/or in replication errors of the RdRp protein between GII.P17 and GII.P4.", [["P17", "GENE_OR_GENE_PRODUCT", 118, 121], ["GII", "GENE_OR_GENE_PRODUCT", 126, 129], ["RdRp protein", "PROTEIN", 93, 105], ["the RdRp protein between GII", "PROBLEM", 89, 117], ["P4", "PROBLEM", 130, 132], ["may be due to", "UNCERTAINTY", 5, 18]]], ["Additional in vitro studies may be needed to address these possibilities.DiscussionWe also assessed the phylodynamics of GII.P17-GII.17 and found that the genome population sizes of GII.P17-GII.17 increased rapidly during 2014\u20132015 and then decreased rapidly thereafter (Figure 4).", [["P17", "GENE_OR_GENE_PRODUCT", 125, 128], ["P17-GII", "GENE_OR_GENE_PRODUCT", 186, 193], ["P17", "PROTEIN", 125, 128], ["GII.17", "DNA", 129, 135], ["P17", "PROTEIN", 186, 189], ["Additional in vitro studies", "TEST", 0, 27], ["P17", "TEST", 125, 128], ["population", "OBSERVATION_MODIFIER", 162, 172], ["sizes", "OBSERVATION_MODIFIER", 173, 178], ["GII", "OBSERVATION", 182, 185], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["rapidly", "OBSERVATION_MODIFIER", 207, 214]]], ["These fluctuations may be associated with epidemics of the newly emerged HuNoV and the acquisition of herd immunity.", [["HuNoV", "CANCER", 73, 78], ["herd", "ORGANISM_SUBDIVISION", 102, 106], ["epidemics", "PROBLEM", 42, 51], ["may be associated with", "UNCERTAINTY", 19, 41]]], ["For example, the fluctuations in the phylodynamics of the GII.4 virus could be associated with the emergence of a variant virus with altered antigenicity and the acquisition of herd immunity to the VP1 capsid protein of that virus (Debbink et al., 2013; Lindesmith et al., 2013; Motoya et al., 2017).", [["GII.4 virus", "ORGANISM", 58, 69], ["VP1", "ORGANISM", 198, 201], ["VP1 capsid protein", "PROTEIN", 198, 216], ["GII.4 virus", "SPECIES", 58, 69], ["the fluctuations", "PROBLEM", 13, 29], ["the GII.4 virus", "PROBLEM", 54, 69], ["a variant virus", "PROBLEM", 112, 127], ["altered antigenicity", "PROBLEM", 133, 153], ["fluctuations", "OBSERVATION_MODIFIER", 17, 29], ["GII.4 virus", "OBSERVATION", 58, 69]]], ["Thus, it is possible that the phylodynamic fluctuations in GII.P17-GII.17 identified in this study are associated with epidemics in various regions and subsequent acquisition of herd immunity (Chan et al., 2015; Fu et al., 2015; Matsushima et al., 2015; Dang Thanh et al., 2016).", [["P17-GII", "GENE_OR_GENE_PRODUCT", 63, 70], ["herd", "ORGANISM_SUBDIVISION", 178, 182], ["P17", "PROTEIN", 63, 66], ["the phylodynamic fluctuations in GII", "PROBLEM", 26, 62], ["this study", "TEST", 88, 98], ["epidemics in various regions", "PROBLEM", 119, 147], ["epidemics", "OBSERVATION", 119, 128]]], ["These results suggest that continuous phylodynamic analysis may provide early notice of other HuNoV epidemics and repeat prevalence of HuNoV, including GII.17.DiscussionWe additionally found amino acid substitutions in the conformational epitopes of the VP1 capsid protein of GII.P17-GII.17 (Figure 5 and Table 2).", [["amino acid", "CHEMICAL", 191, 201], ["amino acid", "CHEMICAL", 191, 201], ["amino acid", "AMINO_ACID", 191, 201], ["conformational epitopes", "PROTEIN", 223, 246], ["VP1 capsid protein", "PROTEIN", 254, 272], ["GII", "PROTEIN", 276, 279], ["continuous phylodynamic analysis", "TEST", 27, 59], ["other HuNoV epidemics", "PROBLEM", 88, 109], ["amino acid substitutions", "PROBLEM", 191, 215], ["the VP1 capsid protein of GII", "PROBLEM", 250, 279], ["P17", "TEST", 280, 283], ["amino", "OBSERVATION", 191, 196], ["acid substitutions", "OBSERVATION", 197, 215]]], ["Such substitutions were also identified around the HBGA binding sites.", [["HBGA binding sites", "DNA", 51, 69], ["Such substitutions", "PROBLEM", 0, 18], ["substitutions", "OBSERVATION", 5, 18]]], ["Such evolutionary substitutions may induce both changes in antigenicity and in HBGA binding ability (Tan et al., 2009; Chen et al., 2011; de Rougemont et al., 2011; Lindesmith et al., 2012; Debbink et al., 2013; Jin et al., 2015).", [["HBGA", "SIMPLE_CHEMICAL", 79, 83], ["Such evolutionary substitutions", "PROBLEM", 0, 31], ["both changes in antigenicity", "PROBLEM", 43, 71]]], ["Indeed, Lindesmith et al. showed that some amino acid substitutions (corresponding to aa394-aa397 in our alignments) are located adjacent of the HBGA binding sites and result in changes in the antigenicity of the GII.17 capsid protein (Lindesmith et al., 2017).", [["amino acid", "CHEMICAL", 43, 53], ["amino acid", "CHEMICAL", 43, 53], ["amino acid", "AMINO_ACID", 43, 53], ["aa394-aa397", "GENE_OR_GENE_PRODUCT", 86, 97], ["HBGA", "GENE_OR_GENE_PRODUCT", 145, 149], ["aa394", "PROTEIN", 86, 91], ["aa397", "PROTEIN", 92, 97], ["HBGA binding sites", "DNA", 145, 163], ["17 capsid protein", "PROTEIN", 217, 234], ["some amino acid substitutions", "PROBLEM", 38, 67], ["aa394", "TEST", 86, 91], ["the HBGA binding sites", "PROBLEM", 141, 163], ["amino", "OBSERVATION", 43, 48], ["acid substitutions", "OBSERVATION", 49, 67], ["binding sites", "OBSERVATION", 150, 163], ["GII", "ANATOMY", 213, 216]]], ["Jin et al. also reported changes to the antigenicities and HBGA binding affinities of GII.17 capsid proteins belonging to different phylogenetic clusters (Jin et al., 2016).", [["HBGA", "SIMPLE_CHEMICAL", 59, 63], ["17 capsid proteins", "PROTEIN", 90, 108], ["the antigenicities", "PROBLEM", 36, 54], ["HBGA binding affinities of GII", "PROBLEM", 59, 89]]], ["Moreover, an amino acid substitution (aa376) located adjacent the HBGA binding sites was identified as a possible positive selection site.", [["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "AMINO_ACID", 13, 23], ["aa376", "AMINO_ACID", 38, 43], ["HBGA", "GENE_OR_GENE_PRODUCT", 66, 70], ["HBGA binding sites", "DNA", 66, 84], ["positive selection site", "DNA", 114, 137], ["an amino acid substitution", "TREATMENT", 10, 36], ["the HBGA binding sites", "PROBLEM", 62, 84], ["positive selection site", "PROBLEM", 114, 137], ["amino", "OBSERVATION", 13, 18], ["acid substitution", "OBSERVATION", 19, 36]]], ["Previous reports have suggested that aa375 and aa377 are associated with the HBGA binding ability (He et al., 2017; Koromyslova et al., 2017); however, to the best of our knowledge, there have been no reports regarding possible roles of the aa376 substitution in antigenicity and the HBGA binding capability, which is a subject for possible further study.DiscussionWe also showed that GII.P17-GII.17 contains amino acid substitutions in residues adjacent to the RdRp active sites and the contact surfaces between RdRp monomers (Figure 6).", [["amino acid", "CHEMICAL", 409, 419], ["amino acid", "CHEMICAL", 409, 419], ["aa375", "GENE_OR_GENE_PRODUCT", 37, 42], ["aa377", "GENE_OR_GENE_PRODUCT", 47, 52], ["HBGA", "GENE_OR_GENE_PRODUCT", 77, 81], ["aa376", "GENE_OR_GENE_PRODUCT", 241, 246], ["HBGA", "GENE_OR_GENE_PRODUCT", 284, 288], ["P17-GII", "GENE_OR_GENE_PRODUCT", 389, 396], ["amino acid", "AMINO_ACID", 409, 419], ["aa375", "DNA", 37, 42], ["HBGA", "PROTEIN", 77, 81], ["HBGA", "PROTEIN", 284, 288], ["P17", "PROTEIN", 389, 392], ["RdRp active sites", "PROTEIN", 462, 479], ["RdRp monomers", "PROTEIN", 513, 526], ["the HBGA binding ability", "PROBLEM", 73, 97], ["the aa376 substitution in antigenicity", "PROBLEM", 237, 275], ["the HBGA binding capability", "PROBLEM", 280, 307], ["further study", "TEST", 341, 354], ["GII", "PROBLEM", 385, 388], ["amino acid substitutions in residues", "TREATMENT", 409, 445], ["the RdRp active sites", "TREATMENT", 458, 479], ["RdRp monomers", "TREATMENT", 513, 526], ["amino acid substitutions", "OBSERVATION", 409, 433], ["RdRp", "OBSERVATION_MODIFIER", 462, 466], ["active", "OBSERVATION_MODIFIER", 467, 473], ["sites", "OBSERVATION_MODIFIER", 474, 479], ["contact surfaces", "OBSERVATION", 488, 504], ["RdRp monomers", "OBSERVATION", 513, 526]]], ["Ng et al. showed that the amino acids around the active sites regulate viral genome replication (Ng et al., 2008).", [["amino acids", "CHEMICAL", 26, 37], ["amino acids", "CHEMICAL", 26, 37], ["amino acids", "AMINO_ACID", 26, 37], ["the amino acids", "TREATMENT", 22, 37], ["the active sites", "TREATMENT", 45, 61], ["viral genome replication", "TREATMENT", 71, 95], ["amino acids", "OBSERVATION", 26, 37], ["active", "OBSERVATION_MODIFIER", 49, 55], ["viral genome", "OBSERVATION", 71, 83]]], ["Moreover, substitutions around the monomer contact surfaces of RdRp affect the stability of the dimer and its RNA binding abilities (Chen et al., 2009).", [["RdRp", "PROTEIN", 63, 67], ["dimer", "PROTEIN", 96, 101], ["substitutions", "PROBLEM", 10, 23], ["RdRp", "PROBLEM", 63, 67], ["stability", "OBSERVATION_MODIFIER", 79, 88]]], ["Thus, the similar substitutions found in the present study warrant additional investigation into changes in the properties of the RdRp protein.", [["RdRp", "GENE_OR_GENE_PRODUCT", 130, 134], ["RdRp protein", "PROTEIN", 130, 142], ["the similar substitutions", "PROBLEM", 6, 31], ["the present study", "TEST", 41, 58], ["additional investigation", "TEST", 67, 91], ["RdRp protein", "OBSERVATION", 130, 142]]], ["Previous studies have also revealed key amino acids associated with the efficiency of HuNoV genome replication (Bull et al., 2010; Eden et al., 2011).", [["amino acids", "CHEMICAL", 40, 51], ["amino acids", "CHEMICAL", 40, 51], ["amino acids", "AMINO_ACID", 40, 51], ["HuNoV genome", "DNA", 86, 98], ["Previous studies", "TEST", 0, 16], ["key amino acids", "PROBLEM", 36, 51], ["amino acids", "OBSERVATION", 40, 51], ["HuNoV genome", "OBSERVATION", 86, 98]]], ["Of these, the threonine residue at aa33 is phosphorylated by a host factor, Akt, and is involved in producing high replication rates (Eden et al., 2011).", [["threonine", "CHEMICAL", 14, 23], ["threonine", "CHEMICAL", 14, 23], ["threonine", "AMINO_ACID", 14, 23], ["aa33", "AMINO_ACID", 35, 39], ["Akt", "GENE_OR_GENE_PRODUCT", 76, 79], ["aa33", "PROTEIN", 35, 39], ["host factor", "PROTEIN", 63, 74], ["Akt", "PROTEIN", 76, 79], ["the threonine residue", "PROBLEM", 10, 31]]], ["This residue is located around the interface between monomers in the RdRp structure.", [["RdRp structure", "PROTEIN", 69, 83], ["This residue", "PROBLEM", 0, 12], ["interface", "OBSERVATION_MODIFIER", 35, 44], ["monomers", "OBSERVATION_MODIFIER", 53, 61], ["RdRp structure", "OBSERVATION", 69, 83]]], ["The RdRp protein of GII.P4 contains a threonine residue at the position, while that of GII.P17 contains an asparagine (data not shown).", [["threonine", "CHEMICAL", 38, 47], ["asparagine", "CHEMICAL", 107, 117], ["threonine", "CHEMICAL", 38, 47], ["asparagine", "CHEMICAL", 107, 117], ["GII", "GENE_OR_GENE_PRODUCT", 20, 23], ["threonine", "AMINO_ACID", 38, 47], ["P17", "GENE_OR_GENE_PRODUCT", 91, 94], ["asparagine", "AMINO_ACID", 107, 117], ["RdRp protein", "PROTEIN", 4, 16], ["GII", "PROTEIN", 20, 23], ["P17", "PROTEIN", 91, 94], ["P4", "PROBLEM", 24, 26], ["a threonine residue", "PROBLEM", 36, 55], ["GII", "PROBLEM", 87, 90], ["an asparagine (data", "TEST", 104, 123], ["RdRp protein", "OBSERVATION", 4, 16], ["threonine residue", "OBSERVATION", 38, 55], ["position", "OBSERVATION_MODIFIER", 63, 71]]], ["This may suggest that the enzyme activity of RdRp differs between the GII.P4 and GII.P17 genotypes.DiscussionWe constructed a genome network of the GII.P17-GII.17 strains examined in this study and found four major clusters (Figure 7).", [["RdRp", "GENE_OR_GENE_PRODUCT", 45, 49], ["P17", "GENE_OR_GENE_PRODUCT", 85, 88], ["P17-GII", "GENE_OR_GENE_PRODUCT", 152, 159], ["RdRp", "PROTEIN", 45, 49], ["P17", "PROTEIN", 152, 155], ["the enzyme activity of RdRp", "PROBLEM", 22, 49], ["17 strains", "PROBLEM", 160, 170], ["this study", "TEST", 183, 193]]], ["Notably, the strains belonging to clusters 1 and 4 were detected exclusively in Japan, while the strains belonging to clusters 2 and 3 were detected from various countries.", [["3", "GENE_OR_GENE_PRODUCT", 133, 134]]], ["Moreover, the two haplotype strains found in Japan might give rise to many variant types.", [["the two haplotype strains", "PROBLEM", 10, 35]]], ["However, we could not determine specific amino acid substitutions in the strains belonging to clusters 1 and 3, which contained the haplotype strains (data not shown).", [["amino acid", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "AMINO_ACID", 41, 51], ["3", "GENE_OR_GENE_PRODUCT", 109, 110], ["specific amino acid substitutions", "PROBLEM", 32, 65], ["the haplotype strains", "PROBLEM", 128, 149], ["acid substitutions", "OBSERVATION", 47, 65]]], ["Thus, these haplotype strains may exhibit no phenotypes acquiring high infectivity due to the mutations, although the reason for this remains unclear at present.", [["these haplotype strains", "PROBLEM", 6, 29], ["phenotypes", "PROBLEM", 45, 55], ["high infectivity", "PROBLEM", 66, 82], ["the mutations", "PROBLEM", 90, 103]]], ["Moreover, the strains belonging to cluster 4 had unique amino acid substitutions in p48, p22, protease, RdRp, and VP2 proteins (data not shown).", [["amino acid", "CHEMICAL", 56, 66], ["amino acid", "CHEMICAL", 56, 66], ["amino acid", "AMINO_ACID", 56, 66], ["p48", "GENE_OR_GENE_PRODUCT", 84, 87], ["p22", "GENE_OR_GENE_PRODUCT", 89, 92], ["protease", "GENE_OR_GENE_PRODUCT", 94, 102], ["RdRp", "GENE_OR_GENE_PRODUCT", 104, 108], ["VP2", "GENE_OR_GENE_PRODUCT", 114, 117], ["p48", "PROTEIN", 84, 87], ["p22", "PROTEIN", 89, 92], ["protease", "PROTEIN", 94, 102], ["RdRp", "PROTEIN", 104, 108], ["VP2 proteins", "PROTEIN", 114, 126], ["unique amino acid substitutions in p48", "TREATMENT", 49, 87], ["protease", "TREATMENT", 94, 102], ["RdRp", "TEST", 104, 108], ["VP2 proteins", "TEST", 114, 126], ["acid substitutions", "OBSERVATION", 62, 80]]], ["These viruses were found only in Miyagi prefecture in Japan, during short periods and was never detected in other areas, perhaps because these mutations are deleterious to the propagations of the virus.", [["These viruses", "PROBLEM", 0, 13], ["these mutations", "PROBLEM", 137, 152], ["the virus", "PROBLEM", 192, 201], ["viruses", "OBSERVATION", 6, 13]]], ["As a limitation, the results of the present analyses may partially be affected by selection bias introduced in the collection of the strains.DiscussionIn conclusion, the GII.P17-GII.17 virus has evolved differently to GII.P4-GII.4.", [["P17-GII", "GENE_OR_GENE_PRODUCT", 174, 181], ["17 virus", "ORGANISM", 182, 190], ["P4-GII", "GENE_OR_GENE_PRODUCT", 222, 228], ["P17", "PROTEIN", 174, 177], ["selection bias", "TEST", 82, 96], ["the strains", "PROBLEM", 129, 140], ["17 virus", "PROBLEM", 182, 190]]], ["However, this virus may have the potential to alter its antigenicity, host-binding capability (i.e., HBGA) and genome replication efficiency.", [["HBGA", "GENE_OR_GENE_PRODUCT", 101, 105], ["HBGA", "PROTEIN", 101, 105], ["this virus", "PROBLEM", 9, 19], ["HBGA", "TEST", 101, 105], ["genome replication efficiency", "PROBLEM", 111, 140], ["replication efficiency", "OBSERVATION", 118, 140]]], ["Such changes could recurrently generate variants of GII.17 with the potential to produce pandemics such as those caused by GII.4 variant strains.", [["Such changes", "PROBLEM", 0, 12], ["GII", "PROBLEM", 52, 55], ["pandemics", "PROBLEM", 89, 98], ["GII.4 variant strains", "PROBLEM", 123, 144]]], ["Thus, additional and continuous evolutionary analyses of this genotype should be needed in the future.Data Availability StatementThe datasets generated for this study can be found in the GenBank and the accession numbers are as follow; LC369214-LC369222, LC369224, LC369225, LC369227-LC369249, LC369251-LC369258, LC486737-LC486770.Ethics StatementThe studies involving human participants were reviewed and approved by the Research and Ethical Committees for the Use of Human Subjects of the National Institute of Infectious Diseases, Tokyo, Japan (No. 576).", [["LC369214-LC369222", "CHEMICAL", 236, 253], ["LC369224", "CHEMICAL", 255, 263], ["LC369225", "CHEMICAL", 265, 273], ["LC369227-LC369249", "CHEMICAL", 275, 292], ["LC369251-LC369258", "CHEMICAL", 294, 311], ["LC486737-LC486770", "CHEMICAL", 313, 330], ["Infectious Diseases", "DISEASE", 513, 532], ["LC369222", "CHEMICAL", 245, 253], ["LC369224", "CHEMICAL", 255, 263], ["LC369225", "CHEMICAL", 265, 273], ["LC369227-LC369249", "CHEMICAL", 275, 292], ["LC369251-LC369258", "CHEMICAL", 294, 311], ["LC486737-LC486770", "CHEMICAL", 313, 330], ["LC369214-LC369222", "SIMPLE_CHEMICAL", 236, 253], ["LC369224", "SIMPLE_CHEMICAL", 255, 263], ["LC369225", "SIMPLE_CHEMICAL", 265, 273], ["LC369227-LC369249", "SIMPLE_CHEMICAL", 275, 292], ["LC369251-LC369258", "SIMPLE_CHEMICAL", 294, 311], ["LC486737-LC486770", "SIMPLE_CHEMICAL", 313, 330], ["human", "ORGANISM", 369, 374], ["Human", "ORGANISM", 469, 474], ["human", "SPECIES", 369, 374], ["participants", "SPECIES", 375, 387], ["Human", "SPECIES", 469, 474], ["human", "SPECIES", 369, 374], ["this genotype", "TREATMENT", 57, 70], ["this study", "TEST", 156, 166], ["The studies", "TEST", 347, 358], ["Infectious", "OBSERVATION", 513, 523]]], ["Informed consent was obtained from all participants, which was acquired from the subjects or their legally acceptable representatives for sample donation.Conflict of Interest ::: Author ContributionsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["participants", "SPECIES", 39, 51], ["sample donation", "TREATMENT", 138, 153]]]], "PMC7179372": [["This collection of short statements from the editors of HERZ/Cardiovascular Diseases is a strong signal to the readers of our journal in critical times.", [["Cardiovascular Diseases", "DISEASE", 61, 84], ["Cardiovascular Diseases", "PROBLEM", 61, 84], ["short", "OBSERVATION_MODIFIER", 19, 24], ["Cardiovascular", "ANATOMY", 61, 75], ["Diseases", "OBSERVATION", 76, 84]]], ["With up-to-date comments, this issue covers a spectrum of questions raised by cardiologists with respect to COVID-19.", [["COVID-19", "DNA", 108, 116], ["COVID", "TEST", 108, 113]]]], "1dc0d5c9114f675403ce720ff5928ef2c8defb97": [["While guidance such as NICE's COVID-19 Rapid Guideline is welcome in navigating complex decisions, the use of the CFS or any short frailty instruments to ration access should be considered cautiously, particularly by those who have not received training in the assessment of frailty.", [["CFS", "DISEASE", 114, 117], ["frailty", "DISEASE", 275, 282], ["NICE's COVID", "TEST", 23, 35], ["the CFS", "TREATMENT", 110, 117], ["any short frailty instruments", "TREATMENT", 121, 150], ["ration access", "TREATMENT", 154, 167], ["training", "TREATMENT", 245, 253], ["the assessment", "TEST", 257, 271], ["frailty", "PROBLEM", 275, 282]]], ["Taking the example of the CFS, while it is the most widely-applied scale in critical care, as with other frailty measures, its reliability and validity needs to be more established in this setting (5) .", [["CFS", "DISEASE", 26, 29], ["other frailty measures", "TREATMENT", 99, 121]]], ["The CFS mixes items such as comorbidity, cognitive impairment and disability (3), and hence its administration requires familiarity with these concepts.", [["CFS", "DISEASE", 4, 7], ["cognitive impairment", "DISEASE", 41, 61], ["disability", "DISEASE", 66, 76], ["The CFS mixes items", "PROBLEM", 0, 19], ["comorbidity", "PROBLEM", 28, 39], ["cognitive impairment", "PROBLEM", 41, 61]]], ["The CFS includes illustrative pictures; however, the detailed text is what matters and there is a risk that untrained, overwhelmed clinicians just refer to these without taking these additional factors into account and without understanding the patients' recent baseline.", [["CFS", "DISEASE", 4, 7], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253]]], ["In \"Fit For Frailty\", the British Geriatrics Society advised that the it should be used to identify the level of frailty only after the completion of a geriatric assessment, which requires talking to patients and often taking a collateral history.", [["frailty", "DISEASE", 113, 120], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["a geriatric assessment", "TEST", 150, 172]]], ["Guidelines must also refer to important factors including illness severity, likelihood of survival and patient preferences otherwise, there is concern that this nuanced complexity may be minimised when units face a surge in cases.", [["illness", "DISEASE", 58, 65], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["illness severity", "PROBLEM", 58, 74]]]], "9cba9cf2af01b8fefe525421a10990c3c8cba881": [["viruses are antigenically distinct from circulating human influenza A(H1) and A(H3) subtypes, cross-protective immunity against variant viruses conferred by recent infection with seasonal influenza viruses or influenza vaccination is likely to be limited.", [["variant viruses", "DISEASE", 128, 143], ["infection", "DISEASE", 164, 173], ["influenza viruses", "DISEASE", 188, 205], ["influenza", "DISEASE", 209, 218], ["human influenza A(H1)", "ORGANISM", 52, 73], ["A(H3) subtypes", "ORGANISM", 78, 92], ["seasonal influenza viruses", "ORGANISM", 179, 205], ["human", "SPECIES", 52, 57], ["seasonal influenza viruses", "SPECIES", 179, 205], ["human influenza A", "SPECIES", 52, 69], ["H1", "SPECIES", 70, 72], ["viruses", "PROBLEM", 0, 7], ["circulating human influenza A(H1)", "PROBLEM", 40, 73], ["A(H3) subtypes", "PROBLEM", 78, 92], ["cross-protective immunity", "TREATMENT", 94, 119], ["variant viruses", "PROBLEM", 128, 143], ["recent infection", "PROBLEM", 157, 173], ["seasonal influenza viruses", "PROBLEM", 179, 205], ["influenza vaccination", "PROBLEM", 209, 230], ["infection", "OBSERVATION", 164, 173]]], ["Although most previous cases of influenza due to variant viruses have occurred after contact with swine, sporadic person-to-person transmission demonstrates the epidemic and pandemic potential of these viruses [2] .", [["influenza", "DISEASE", 32, 41], ["swine", "SPECIES", 98, 103], ["person", "SPECIES", 114, 120], ["-person", "SPECIES", 123, 130], ["swine", "SPECIES", 98, 103], ["influenza", "PROBLEM", 32, 41], ["variant viruses", "PROBLEM", 49, 64], ["the epidemic", "PROBLEM", 157, 169], ["these viruses", "PROBLEM", 196, 209]]]], "11457f1b694fd129e356be351b5b4dbea9b61977": [["'COVID-19 Lockdown: A protective measure or exacerbator of health inequalities?", [["A protective measure", "TREATMENT", 20, 40]]], ["A commentary on \"The socio-economic implications of the coronavirus and COVID-19 pandemic: A review\" Dear Editor,", [["coronavirus", "DISEASE", 56, 67], ["coronavirus", "ORGANISM", 56, 67], ["the coronavirus", "PROBLEM", 52, 67]]]], "db45086800c677cdf1d4dd863da6177f95b98e6f": [["Since then, these recommendations have been implemented and the blood safety community (blood collectors, blood safety experts, and relevant Federal agencies) has responded to other emerging infectious disease (EID) threats, such as West Nile virus (WNV) and most recently the xenotropic murine leukemia virus-related virus (XMRV).", [["blood", "ANATOMY", 64, 69], ["blood", "ANATOMY", 88, 93], ["blood", "ANATOMY", 106, 111], ["infectious disease", "DISEASE", 191, 209], ["EID", "DISEASE", 211, 214], ["West Nile virus (WNV)", "DISEASE", 233, 254], ["xenotropic murine leukemia virus", "DISEASE", 277, 309], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["West Nile virus", "ORGANISM", 233, 248], ["WNV", "ORGANISM", 250, 253], ["xenotropic murine leukemia virus-related virus", "ORGANISM", 277, 323], ["XMRV", "ORGANISM", 325, 329], ["West Nile virus", "SPECIES", 233, 248], ["murine", "SPECIES", 288, 294], ["leukemia virus-related virus", "SPECIES", 295, 323], ["West Nile virus", "SPECIES", 233, 248], ["WNV", "SPECIES", 250, 253], ["xenotropic murine leukemia virus-related virus", "SPECIES", 277, 323], ["blood collectors", "TEST", 88, 104], ["West Nile virus (WNV", "PROBLEM", 233, 253], ["the xenotropic murine leukemia virus", "PROBLEM", 273, 309], ["xenotropic murine leukemia virus", "OBSERVATION", 277, 309]]], ["Responding to any new threat entails assessing the risk to the blood supply and recipients' health; evaluating how best to manage and/or control each potential risk; and communicating this information to blood donors, recipients, physicians, and the general public.", [["blood", "ANATOMY", 63, 68], ["blood", "ANATOMY", 204, 209], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 204, 209]]], ["Although the FDA has the regulatory authority to develop guidance documents and new regulations in response to EID threats based on available data, the challenge of generating that data and responding to potential risks requires concerted and coordinated actions by the multiple PHS agencies (Centers for Disease Control and Prevention [CDC] , FDA, National Institutes of Health [NIH] ) and by the broader transfusion medicine community (AABB and blood providers).", [["blood", "ANATOMY", 447, 452], ["blood", "ORGANISM_SUBSTANCE", 447, 452], ["EID threats", "TEST", 111, 122], ["Disease Control", "TREATMENT", 305, 320]]], ["It is therefore incumbent upon the transfusion medicine professionals to collect and provide robust data in a timely manner to policymakers to inform their decision process, as well as take an active role in risk communication.", [["the transfusion medicine professionals", "TREATMENT", 31, 69]]], ["All stakeholders must recognize what they can do and provide leadership and timely research and risk assessments.", [["risk assessments", "TEST", 96, 112]]], ["Such a process does not involve a confirmation or criticism of what has been done in previous responses to potential threats to the blood supply, but an assessment of how responses can be improved for future threats.", [["blood", "ANATOMY", 132, 137], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["an assessment", "TEST", 150, 163]]]], "8070446af65ce809c7b0faaf5e106a4f228e21a1": [["INTRODUCTIONWithin medicine, rates of clinician burnout have reached endemic levels, with emergency physicians reporting amongst the highest rates of burnout.", [["burnout", "DISEASE", 48, 55], ["burnout", "DISEASE", 150, 157]]], ["1 Complementing this concept of burnout is the idea of clinician well-being, defined as an \"active process of becoming aware of and making choices toward a healthy and fulfilling life.\" 1 The recognition of clinician burnout and support of physicians to ensure well-being are critical not only for career satisfaction but also patient care outcomes.INTRODUCTIONPhysicians reporting higher rates of burnout have been associated with both reduced career satisfaction and adverse patient care outcomes.", [["burnout", "DISEASE", 32, 39], ["burnout", "DISEASE", 398, 405], ["patient", "ORGANISM", 327, 334], ["patient", "ORGANISM", 477, 484], ["patient", "SPECIES", 327, 334], ["patient", "SPECIES", 477, 484]]], ["2, 3 Currently, well-being and burnout have been largely conceptualized as a singular construct of which the causes are the same for all physicians, across all specialties and across the professional lifespan.", [["burnout", "DISEASE", 31, 38]]], ["3 That is to say, perhaps solutions for an emergency medicine resident, a newly graduated emergency physician practicing for <10 years, a physician 10-20 years post-graduation, and a latecareer physician in the final years of clinical work may be unique and differ depending on the individual career stage.INTRODUCTIONThe life cycle of an emergency physician has never been comprehensively studied with regard to the causes of burnout and well-being.INTRODUCTIONSolutions in the past have primarily focused on encouraging individuals to improve themselves with techniques to reduce stress rather than on the external and environmental factors that place the individual under increasing demands and stress.", [["burnout", "DISEASE", 427, 434], ["burnout", "PROBLEM", 427, 434], ["techniques", "TREATMENT", 561, 571], ["stress", "PROBLEM", 582, 588]]], ["5 The National Academy of Medicine Action Collaborative on Clinician Well-Being and Resilience recently introduced a conceptual model in 2018 updating a working definition of burnout to emphasize that extrinsic and environmental JACEP Open 2020;1-5.INTRODUCTIONwileyonlinelibrary.com/journal/emp2 factors affect physicians' well-being.", [["burnout", "DISEASE", 175, 182], ["journal/emp2 factors", "PROTEIN", 284, 304]]], ["The goal of this concept article is to provide a novel framework for describing well-being and conceptualizing causes of burnout as a dynamic construct posing unique challenges across the professional lifespan of clinicians from trainees to new faculty to senior clinicians.THE TRAINEE AND EARLY CAREER EMERGENCY PHYSICIAN (<10 YEARS POST-GRADUATION)Well-being, resilience, and burnout are important concepts throughout the professional life span of emergency clinicians.", [["burnout", "DISEASE", 121, 128], ["burnout", "DISEASE", 378, 385], ["burnout", "PROBLEM", 121, 128]]], ["Trainees and early faculty appear to suffer from high rates of clinician burnout and emotional fatigue.", [["burnout", "DISEASE", 73, 80], ["emotional fatigue", "DISEASE", 85, 102], ["emotional fatigue", "PROBLEM", 85, 102]]], ["7, 7 Although many of the challenges encountered by young physicians are also shared by more established clinicians, burnout in the early-career emergency physician is marked by the presence of unique stressors.", [["burnout", "DISEASE", 117, 124]]], ["Training and much of the early years as young faculty is marked by expectations of formal and informal assessments, in addition to structured educational responsibilities, all occurring in the context of a steep learning curve experience at the bedside.", [["informal assessments", "TEST", 94, 114], ["marked", "OBSERVATION_MODIFIER", 57, 63]]], ["8 This milieu of frequent standardized testing and assessments has been reported to be a significant driver of self-reported stress among trainees.", [["frequent standardized testing", "TEST", 17, 46], ["assessments", "TEST", 51, 62]]], ["9 Additionally, although not unique to young faculty, concern for acknowledging diagnostic uncertainty and revealing errors to other physicians also have been found to be prevalent among trainees and early faculty and associated with increased levels of burnout and early career dissatisfaction.", [["burnout", "DISEASE", 254, 261], ["increased levels of burnout and early career dissatisfaction", "PROBLEM", 234, 294]]], ["10 Past work has found that other diverse stressors, ranging from familial obligations, social support, and perceived lack of administrative autonomy were associated with increased levels of burnout.", [["burnout", "DISEASE", 191, 198], ["social support", "TREATMENT", 88, 102], ["increased levels of burnout", "PROBLEM", 171, 198], ["burnout", "OBSERVATION", 191, 198]]], ["6 For many trainees and young faculty, the challenges of professional development occur alongside significant financial obligations as well as personal milestones, including relationships and family planning.THE TRAINEE AND EARLY CAREER EMERGENCY PHYSICIAN (<10 YEARS POST-GRADUATION)Recent work by West et al, 11 found that greater educational debt was associated with burnout symptoms, with a debt over $200,000 associated with almost double the odds of having at least one symptom of burnout.", [["burnout", "DISEASE", 370, 377], ["burnout", "DISEASE", 487, 494], ["burnout symptoms", "PROBLEM", 370, 386], ["burnout", "OBSERVATION", 487, 494]]], ["This combination of professional, financial, and personal demands for early-career clinicians may create a period of increased vulnerability for the development of burnout symptoms such as emotional exhaustion, and if not dealt with early on, may lead to sustained effects lasting throughout the professional lifespan of such clinicians.THE JUNIOR TO MID-CAREER EMERGENCY PHYSICIAN (10-20 YEARS POST-GRADUATION)Compared to early and later careers, mid-career is an especially challenging time for physicians.", [["burnout", "DISEASE", 164, 171], ["increased vulnerability", "PROBLEM", 117, 140], ["burnout symptoms", "PROBLEM", 164, 180], ["emotional exhaustion", "PROBLEM", 189, 209]]], ["\"Mid-career Crisis Syndrome\" is a common phenomenon across many career paths.", [["Mid-career Crisis Syndrome", "PROBLEM", 1, 27], ["a common phenomenon", "PROBLEM", 32, 51], ["Crisis Syndrome", "OBSERVATION", 12, 27]]], ["This \"syndrome\" results in the successful individual feeling unsatisfied, stagnant, losing self-confidence, or losing a sense of purpose.", [["This \"syndrome", "PROBLEM", 0, 14]]], ["The \"crisis\" appears to stem from mid-career physicians arriving at a transition point within their career paths.", [["The \"crisis", "PROBLEM", 0, 11]]], ["13 The imposter syndrome and the concern for medical errors are less acute.", [["The imposter syndrome", "PROBLEM", 3, 24], ["medical errors", "PROBLEM", 45, 59], ["syndrome", "OBSERVATION", 16, 24], ["less", "OBSERVATION_MODIFIER", 64, 68], ["acute", "OBSERVATION_MODIFIER", 69, 74]]], ["13 Similar to physicians of other stages in their career, mid-career physicians deal with many factors contributing to their overall lack of well-being and burnout burden.", [["burnout", "DISEASE", 156, 163], ["burnout burden", "PROBLEM", 156, 170]]], ["However, unlike other disciplines, the pathway to operationalizing seniority among emergency physicians is less clear.", [["less", "OBSERVATION_MODIFIER", 107, 111], ["clear", "OBSERVATION", 112, 117]]], ["For example, orthopedic faculty often begin their careers with full involvement in a wide range of orthopedic illnesses and injuries and, as they mature in their professional lives transition to performing a singular procedure.", [["injuries", "DISEASE", 124, 132], ["orthopedic illnesses", "PROBLEM", 99, 119], ["injuries", "PROBLEM", 124, 132], ["a singular procedure", "TREATMENT", 206, 226]]], ["Similarly, OBGYN physicians initially start their careers with a broad scope of procedures and then may transition to perform solely gynecologic procedures.", [["a broad scope of procedures", "TREATMENT", 63, 90], ["solely gynecologic procedures", "TREATMENT", 126, 155]]], ["16 Given the relative newness of emergency medicine, the expected maturation of the emergency physician is yet to be determined.", [["emergency medicine", "TREATMENT", 33, 51]]], ["In addition, the workplace environment and location of practice: urban versus rural location or community versus academic, contribute to an individual's level of burnout.", [["burnout", "DISEASE", 162, 169]]], ["19 As a specialty, we need to look holistically at well-being education and interventions to comprehensively support the clinician's on-going career.", [["interventions", "TREATMENT", 76, 89]]], ["It is vitally important to incorporate factors such as generational differences, the effects of roles and ever-changing responsibilities, gender identity and race, location of prac- Other alternatives include transitioning to full administrative duties, a strictly academic role or \"re-inventing\" themselves in online educational platforms, blogs, free-standing telemedicine \"emergency departments\" and board certification preparation courses.", [["board certification preparation courses", "TREATMENT", 403, 442]]], ["22 Physicians also have opted to transition to locum tenens affording them complete control of scheduling and allowing them to pursue projects outside of clinical work.", [["locum tenens", "TREATMENT", 47, 59]]], ["For these physicians, supplementary income may include paid lectures, expert witness testimony, and increased administrative duties with a reduced clinical load.", [["a reduced clinical load", "PROBLEM", 137, 160]]], ["Without a pathway for the clinical maturation for emergency physicians, senior physicians may have no alternative but to leave clinical medicine or transition to another specialty creating an unfortunate loss of collective wisdom and clinical experience.THE ESTABLISHED EMERGENCY PHYSICIANS (21-30 YEARS POST-GRADUATION)A study of over 30,000 emergency physicians showed that of the physicians who had a career change, 45% opted to work in a non-emergency medicine clinical practice and the rate of attrition at 30 years postgraduation was 25%.", [["clinical medicine", "TREATMENT", 127, 144], ["A study", "TEST", 320, 327]]], ["23 As a specialty, we must simultaneously create a work environment to retain the mid-career and senior emergency physicians while supporting growth in trainees and early career physicians.THE ESTABLISHED EMERGENCY PHYSICIANS (21-30 YEARS POST-GRADUATION)One solution is the establishment of peer mentoring and focus groups for different life stages to determine best practices for each of those stated stages.", [["peer mentoring", "TREATMENT", 292, 306]]], ["Although systemic issues remain, early-career physicians may benefit from mentors who focus on work-life harmony, clinical knowledge, and financial advice.", [["systemic issues", "PROBLEM", 9, 24]]], ["In addition, developing relationships and learning about the challenges of retirement may benefit physicians who are close to making the transition to retirement.THE ESTABLISHED EMERGENCY PHYSICIANS (21-30 YEARS POST-GRADUATION)Mentoring and focus groups are likely not enough to curb this phenomenon.", [["likely not", "UNCERTAINTY", 259, 269]]], ["Well-being research addressing emergency medicine system challenges across different career stages may help physicians thrive over the span of their career.", [["emergency medicine system", "TREATMENT", 31, 56]]], ["This idea is consistent with a study involving mostly primary care physicians that found that \"dayto-day practice issues\" were key factors in physician satisfaction.", [["a study", "TEST", 29, 36], ["consistent with", "UNCERTAINTY", 13, 28]]], ["24 The survey study also found that specific components (ie, family demands), varied between subgroups depending on gender and practice location.", [["The survey study", "TEST", 3, 19]]], ["24 By studying individualized factors across career lifespans, the results may help develop specific well-being interventions allowing individuals and organizations to create a supportive working environment and allowing physicians to finish their career through a clinical path.CLINICIAN WELL-BEING IN THE COVID-19 PANDEMICThe emergence of COVID-19 as a pandemic affecting the world in late 2019 has resulted in a tremendous strain on existing health care systems, particularly among health care workers in emergency medicine.", [["COVID-19", "CHEMICAL", 341, 349], ["COVID", "TEST", 341, 346], ["a tremendous strain", "PROBLEM", 413, 432], ["tremendous", "OBSERVATION_MODIFIER", 415, 425]]], ["Early data have found significant rates of depression and anxiety among emergency responders to the pandemic and this number is only expected to grow.", [["depression", "DISEASE", 43, 53], ["anxiety", "DISEASE", 58, 65], ["depression", "PROBLEM", 43, 53], ["anxiety", "PROBLEM", 58, 65], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["depression", "OBSERVATION", 43, 53]]], ["25 Well-being initiatives supporting staff across the lifespan during this crisis should include offering departmental mental health resources, ranging from behavioral health specialists to peer support sessions.", [["this crisis", "PROBLEM", 70, 81]]], ["In addition to psychological stressors, COVID-19 has presented unique challenges for clinician well-being, as threats to physical well-being (eg, disease exposure and transmission) are acutely elevated.", [["COVID-19", "CHEMICAL", 40, 48], ["acutely elevated", "PROBLEM", 185, 201], ["elevated", "OBSERVATION_MODIFIER", 193, 201]]], ["Advanced-age emergency clinicians or those with existing medical comorbidities may be at elevated risk of disease severity, and strategies should be considered to mitigate that risk.", [["existing medical comorbidities", "PROBLEM", 48, 78], ["disease severity", "PROBLEM", 106, 122], ["disease", "OBSERVATION", 106, 113]]], ["Regardless of age, high levels of psychological distress and fatigue will likely be prevalent.", [["psychological distress", "DISEASE", 34, 56], ["fatigue", "DISEASE", 61, 68], ["psychological distress", "PROBLEM", 34, 56], ["fatigue", "PROBLEM", 61, 68]]], ["Emergency medicine departments nationally and individually need to examine these pressing issues and address them across the generations to provide relevant and timely assistance.CLINICIAN WELL-BEING IN THE COVID-19 PANDEMICAs the specialty of emergency medicine continually evolves, the professional life span of the emergency physician plays a key part of this conversation.", [["emergency medicine", "TREATMENT", 244, 262]]], ["Promoting targeted well-being education and initiatives will aid emergency physicians to ride the generational waves of financial challenges, job satisfaction vacillations, career transitions, clini-cal competencies, and national medical emergencies ideally supporting them to continue their careers and lifelong professional development in a satisfying and rewarding manner.AUTHOR CONTRIBUTIONSJC, BC, RM, and JK all participated in concept design, drafting of the manuscript, and critical revision of the manuscript for important intellectual content.", [["BC", "TEST", 399, 401], ["critical revision", "TREATMENT", 482, 499], ["important intellectual content", "PROBLEM", 522, 552], ["revision", "OBSERVATION", 491, 499]]], ["JC oversaw all phases of manuscript production and takes final responsibility for it's submission.Jenny L. Castillo MDhttps://orcid.org/0000-0002-5054-7480", [["JC", "DISEASE", 0, 2], ["Jenny L. Castillo MDhttps://orcid.org/0000-0002-5054-7480", "SPECIES", 98, 155], ["all phases", "OBSERVATION_MODIFIER", 11, 21]]]]}